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ABSTRACT 
Positron emission tomography (PET) imaging is a quickly developing area of 
research that allows non-invasive visualisation of molecular processes in vivo.1  PET 
imaging offers a three dimensional image with picomolar sensitivity of the processes 
in the body.  This technique requires the development of specific molecules with high 
affinity for the process to be examined with the incorporation of a radiolabel, usually 
a short-lived positron emitting radionuclide such as 11C, 13N, 15O, 18F.  The half-life of 
the radionuclide must allow chemical incorporation and purification of the target 
molecule. 
In this investigation, two such probes are being studied to establish rapid 
reactions for the key steps that introduce the radioisotopes. This requires model 
studies and/or revised synthetic routes to target molecules that will interact with the 
muscarinic acetylcholine receptor.2,3 Imaging based on such receptors has 
applications with Alzheimer’s disease (AD) which is the most common 
neurodegenerative disease, involving the gradual and progressive memory loss and 
dementia. 
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2 
MODEL STUDIES FOR FAST REACTIONS FOR PET IMAGING APPLICATIONS 
1.0 POSITRON EMISSION TOMOGRAPHY 
Molecular imaging is a rapidly developing area of research allowing the 
visualisation and characterisation of biological processes in vivo without the need for 
invasive surgery.  Positron emission tomography (PET) is one such quantitative 
technique offering picomolar sensitivity using radiolabelled probes to target the 
desired biological process.   
PET imaging is used both in research and clinical medicine, in particular in the 
fields of oncology, neurology, cardiology, psychiatry and pharmacology.  PET 
imaging has important applications in the field of drug design with the 
characterisation of target molecules in vivo, visualising bioavailability, metabolism 
and metabolite distribution.  PET imaging is an attractive technique as only small 
quantities of tracer are required to generate images; this has significant benefits to 
patients as toxic effects of drugs are reduced at low dose.    
The idea of emission tomography was first proposed by David Kuhl and Roy 
Edwards in the 1950s with their work leading to the design and construction of 
tomographic instruments.  This work was developed further by many individuals; the 
contributions of Gordon Brownell, William Sweet and Charles Burnham led to the 
first demonstration of annihilation imaging for use in medicine. 
Positron emission is a type of beta decay, or β+ decay, whereby a proton is 
converted into a neutron, positron and a neutrino, as summarised in Scheme 1.0.4 
 
 
Scheme 1.0 Equation describing β+ decay of 11C to 11B 
 
The positron emitted through this process slows in speed before undergoing 
an annihilation reaction between the positron and electron in the shell of a 
neighbouring atom.  Typically this is in the order of one millimetre in distance from 
the point of beta decay.  Upon annihilation two gamma rays with energy 511 keV are 
produced travelling in diametrically opposing directions.  These gamma rays are 
detected by a coincidence counting detection system.  After a filtering process, this 
information is used to re-construct a cross-sectional image as depicted in Figure 1.0. 
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Figure 1.0 Overview of PET scanning process5 
 
The majority of radionuclides are artificially produced in a cyclotron reactor.  
More than 300 nuclides are known of which 270 are stable and the remainder are 
radioactive.  In PET imaging, only positron-emitting radionuclides are required, and 
relatively few positron-emitting radionuclides have been successfully utilised in 
clinical applications.  These radionuclides include 11C, 13N, 18F, 15O.  These 
radionuclides are produced in a medical cyclotron usually on site at the point of 
administration due to their short half-lives. 
Medical cyclotrons are compact cyclotrons that are primarily used to produce 
short-lived radionuclides, by nuclear reactions using low-energy particles.  
Commonly in medical cyclotrons hydride ions, H-, are preferred as the cyclotron 
housing does not become radioactive as is the case with positive ion cyclotrons. 
Some of the most common PET nuclides and their characteristics are given in 
Table 1.0.  The radionuclides are short lived; this puts limitations on the synthesis 
time for PET radiopharmaceuticals.  However, the attractive advantage of using such 
radionuclides is that the ligands (radiolabel) can be incorporated into biological 
g amm a ra ys e mitte d
5 11 keV
a nnihilatio n b e t ween p o s itro n (black)       
a n d e le ct ron (blu e )
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receptors and therefore often depict a true representation of biological processes in 
vivo. 
Nuclide Physical half-
life (t1/2) 
Mode of decay 
(%) 
γ-ray energy 
(keV) 
Abundance 
(%) 
11C 20.4 min β+ (100) 511 200 
13N 10 min β+ (100) 511 200 
15O 2 min β+ (100) 511 200 
18F 110 min β+ (97) 511 194 
 
Table 1.0. Characteristics of common positron emitters 
 
Perhaps the most well known examples are 18F-fluorodeoxyglucose (FDG) 
(Scheme 1.01) which is used as an analog of glucose for cellular metabolism and 
H2
15O for cerebral perfusion.   
 
The first synthesis of 18F-FDG was carried out by Wolf et al. in 1976 via 
electrophilic fluorination. The synthesis subsequently carried out by Fowler et al. is 
depicted in Scheme 1.01.6,7  
 
Scheme 1.01 Synthesis of 18F-FDG 
 
The electrophilic fluorination carried out by Fowler et al. involved the use of 4, 
6-tri-O-acetyl-D-glucal as the precursor.  The glucal was treated with F2 (with mono 
substituted fluorine-18) to yield a 3:1 mixture of the desired difluoro-glucose and the 
undesired difluoro-mannose.  The difluoro-glucose was separated and hydrolysed to 
yield 2-fluoro-2-deoxyglucose (FDG) in 8% yield in two hours.7,8  Despite a long 
synthetic process and low yield they went on to map glucose metabolism in the 
brain, constituting the first human trial of 18F-FDG.6,7    
Fluorine-18 is widely preferred since it has a relatively long half-life that allows 
production and distribution to remote locations.  In all examples of 
radiopharmaceuticals, a suitable synthetic method is designed to provide a stable 
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product with good labelling yield, high specific activity, high purity and perhaps most 
importantly high in vivo tissue selectivity.   
Fluorine-18 is produced by irradiation of 18O-water with 10 to 18 MeV protons 
in a cyclotron and recovered as 18F-sodium fluoride by passing the irradiated water 
target mixture through a carbonate type anion exchange resin column.  The water 
passes through and the 18F- is trapped on the column.  This can be subsequently 
recovered by washing with potassium carbonate solution to form a solution of K18F. 
Oxygen-15 can be prepared as 15O-water and n-15O-butanol.  The former is 
prepared in the cyclotron by the 15N(p,n)15O (or 14N(d,n)15O) reaction.  The irradiated 
gas is transferred to a 15O-water generator in which 15O is combined with hydrogen 
over a palladium/charcoal catalyst at 170oC.9,10,11  The resulting H2
15O vapour is 
trapped in saline and passed through a membrane filter.  The sample is often 
injected online straight into the patient given the short timeframe in which it is 
necessary to work.   
The latter, n-15O-butanol, is prepared by the reaction of 15O (preparation 
described above), with tri-n-butylborane loaded on an alumina Sep-Pak cartridge.  
15O-butanol is eluted from the cartridge with ethanol/water.11,12 
Nitrogen-13 has been isolated as 13N-ammonia, produced by the reduction of 
13N-labelled nitrates and nitrites from the proton irradiation of water in a cyclotron.  
The reduction is carried out in in alkaline conditions.  13N-ammonia can then be 
distilled and trapped in saline solution under acidic conditions.11,13 The resulting 
solution is then purified through anion exchange resins and passed over a 
membrane filter.  Careful control of the pH is required to remain between 4.5 and 
7.5. 
Carbon-11 can be prepared as 11C-CO2, and thus used to prepare a variety of 
different compounds that include: 11C-sodium acetate, 11C-flumazenil, 11C-L-
methionine, 11C-raclopride and 11C-methylspiperone (MSP) (Figure 1.01). One of the 
common radiolabel precursors is the use of 11C-iodomethane for N-methylation.  11C-
MeI is prepared from the reduction reaction of 11CO2. 
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Figure 1.01 Molecular structures of 11C-flumazenil (1), 11C-methylspsperone (MSP) 
(2), 11C-L-methionine (3), 11C-raclopride (4) 
 
The first step in developing new probes for positron emission tomography is 
the identification of the target, which generally consists of an enzyme, a transporter 
or a receptor.1,14 Once the target has been identified, ligands for the target need to 
be selected, either by rational design based on structural biology1,15 or by high 
throughput screening of libraries of compounds, or by a combination of both. In the 
latter case, libraries are generally selected based on rational design to speed up the 
process by limiting the number of compounds to be screened.1,16  
Our approach to choosing targets for this project is based on the idea of 
“mining” published but non-commercialised pharmaceutical agents.  Such a selection 
process could identify target molecules suitable for use as PET contrast agents from 
the pool of pharmaceutical compounds that have failed clinical trials for therapeutic 
treatment of conditions because of problems with toxicity, efficacy, etc.   
While such compounds may not be suitable for treatment of chronic/acute 
conditions due to toxic or adverse events over an extended period of time, such a 
target may exhibit the required specificity and affinity for a particular enzyme or 
receptor which would make it suitable as a PET contrast agent given it is delivered 
as a single low dose.  Similarly, while a particular compound may not exhibit the 
required efficacy to progress onto further clinical trials and become an effective 
treatment for a given condition, it is not to say these compounds do not have again 
the required specificity and affinity for a given biological process that would make it 
suitable as a PET contrast agent. 
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On this basis, the compounds discussed below have been chosen from 
classes of compounds that have not been developed into therapeutic treatments but 
have been shown to possess good affinity and specificity for their respective 
receptors.  Clearly this type of methodology of screening the vast numbers of drugs 
that have failed clinical trials would almost certainly generate huge libraries of 
compounds, and to consider each target in turn is beyond the scope of this project.  
Consequently, it was decided to aim our efforts at a particular disease area to refine 
the selection process.  Thus, our efforts were focused on Alzheimer’s disease (AD) 
for reasons of potential collaboration with other groups with a similar interest through 
the Interreg program and Innovative Synthesis, Culture and Entrepreneurship 
(IS:CE). 
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1.1 ALZHEIMER’S DISEASE 
Increasing life expectancy of the population makes Alzheimer’s disease (AD) 
a growing public health problem, so there is great need to find ways to prevent and 
delay the disease.17  AD is a progressive, neurodegenerative disease accounting for 
60–70% of dementia cases in the elderly with no current modifying treatment.16 AD 
disease accounts for most cases of dementia that are diagnosed after the age of 60 
years. It affects 20–30 million individuals worldwide.18,19 The prevalence of AD 
increases with age and life expectancy is constantly increasing in developed 
countries, it has been predicted that the incidence of AD will increase threefold over 
the next 50 years. 
The progression of AD is different for each individual; however there are 
similarities in the symptoms experienced by sufferers with patterns in cognitive and 
functional impairments.  Symptoms often include memory loss, confusion, irritability, 
language breakdown, aggression and withdrawal.  The earliest symptoms are 
commonly mistaken for the natural progression of ageing or stress, given that 
memory loss is common to all ageing individuals.20  
As the disease progresses patients require increasing levels of care, and 
often patients present with increasing severity of symptoms to the point of fatality.  
Currently no cure is available for AD so the primary concern is the management of 
patient symptoms that falls to a carer.  This has a significant impact on such a care 
giver, often a spouse or relative, with respect to physical, psychological and 
economic burden.21,22 AD accounts for the highest economic burden on society in 
developed countries.22,23 
The cause and progression of AD is not currently understood.  Most recent 
research has been directed into clinical markers associated with the disease and risk 
factors associated with the onset of AD.  It is thought the disease is associated with 
amyloid plaques and tangles found in the brain.22,24  While the complete prevention 
of AD is unlikely with our current understanding, there are lifestyle habits that are 
thought to slow the onset and progression of the disease with exercise, balanced 
diet and mental stimulation that have been found to slow the onset of AD.22,25  
“Finding AD risk-factor genes is essential for understanding the very early 
biological steps that lead to the vast majority of AD cases and for developing drugs 
and other prevention and treatment strategies. Finding these genes also will help 
scientists develop better ways to identify people at risk of AD and determine how the 
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genes may interact with other genes or with lifestyle or environmental factors to 
affect an individual’s AD risk”.25   
 
1.2 AIMS OF THE PROJECT 
In this investigation we set out to achieve the development of a route to PET 
contrast agents by offering a robust synthetic protocol to allow the incorporation of 
carbon-11 radionuclides by selective N-alkylation of pyridine rings and subsequent 
regioselective reduction to yield 1-alkyl-tetrahydropyridine moieties.  Offering this 
protocol would allow the synthesis of a wide variety of compounds to gain new 
insight into the target M1 muscarinic receptor and its effect on the progression of AD. 
 Once we have established a general protocol we will look to synthesise an 
example of an M1 muscarinic receptor agonist, based on current publications, to 
demonstrate the application of the developed protocol as well as gaining experience 
with the challenges of synthesising PET contrast agents. 
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2.0 MUSCARANIC RECEPTOR 
Muscarinic acetylcholine receptors (mAChRs) are G protein-coupled 
acetylcholine receptors found predominantly in the plasma membranes of neurons 
and other cells.  They play various roles predominately mediating the metabotropic 
(signal transduction) action of acetylcholine. Muscarinic receptors are classified into 
five sub-types M1-M5, their location and function is given in Table 2.0. 
mAChRs sub-type: Location: Function: 
M1 • Central nervous 
system (CNS) 
• secretions from salivary 
glands 
• memory 
M2 • CNS 
• heart 
• slow heart rate 
• reduce contraction force 
of atrium 
• reduce conduction speed 
of AV node 
M3 • CNS 
• eye 
• digestive system 
• muscular system 
• smooth muscle 
contraction 
• vasodilation 
• secretions from 
endocrine/exocrine glands 
• induce emesis 
M4 • CNS • enhance locomotion 
M5 • CNS • not fully understood 
 
Table 2.0 Location and function of mAChRs sub-types in human body26,27 
 
Muscarinic acetylcholine receptor subtypes have been the subjects of 
research for at least a quarter of a century. Nonetheless, there are few selective 
muscarinic receptor ligands presently used as therapeutics.28 There has been 
extensive research into the role of M1 mAChR agonists and their effect on cognitive 
dysfunctional conditions such as AD, but as yet no successful drug candidate has 
been developed from such research suggesting a lack of understanding of the role 
played by M1 mAChRs in dementia.  
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Highly selective mAChRs subtype antagonists have been developed - the 
best of which were extracted from snake venom.29 However, with the exception of 
pirenzepine (Figure 2.0), few have been further developed into novel therapeutic 
treatment for cognitive dysfunction.30,31  
 
Figure 2.0 Structure of pirenzepine, mAChRs M1 antagonist
 
 
By contrast, M1 selective mAChRs agonists have been developed with initial 
success for the treatment of AD, and also other conditions associated with cognitive 
dysfunction. The M1 mAChRs are widely found in the CNS (Table 2.0), located 
predominately in the cortex and hippocampus, and are known to be associated with 
learning and memory.32 Both of these areas have been established as areas of the 
brain that develop amyloid plaques during the progression of AD.  As such M1 
mAChRs have been identified as a potential therapeutic target since AD is known to 
progress through a decreased activity in cholinergic activity in the brain thus 
reducing functional signalling capacity in the brain.  It has been shown that this 
decrease in cholinergic activity is not due to depletion in mAChRs G-protein coupled 
receptors but rather a decrease in the number of receptors in an agonist stimulated 
state.33,34  
Many pharmaceutical companies have pursued the development of specific 
M1 mAChRs agonists for the treatment of cognitive dysfunction, including arecoline, 
cevimeline, tazomeline, alvameline, talsaclidine, xanomeline, milameline and 
sabcomeline.  While many of these compounds progressed to pre-clinical trials 
showing good efficacy towards cognitive dysfunction, many were withdrawn either 
due to poor side effect profiles or unacceptable safety margins.   
Such side effects in general arise from not only the stimulation of M1 subtypes but 
also M2 and M3 subtypes.  Candidates experienced associated cholinergic side 
effects including salivation, lacrimation and gastro-intestinal disturbances.35  Low 
doses administered to candidates in an attempt to limit possible side effects were not 
found to possess sufficiently satisfactory efficacy to proceed into clinical trials.  This 
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demonstrates a further lack of understanding in the development of selective M1 
mAChRs agonists.   
Most of the compounds given above are derived from arecoline (Figure 2.01), 
an alkaloid natural product found in the areca nut of the areca palm.  Arecoline itself 
is a partial agonist of M1, M2 and M3 mAChRs subtypes and as such has been 
shown to improve memory in AD patients.  However, is not recommended due to its 
possible carcinogenic effects.36,37  
 
Figure 2.01 Structure of arecoline 
 
Arecoline was first synthesised in 1951 by J. J. Panouse38 from nicotinic acid, 
and then subsequently optimised by N. Kinoshita in 196239 and I. A. Kozello in 
1976.40 The reaction scheme for Kozello’s synthetic strategy is depicted in Scheme 
2.0. 
 
Scheme 2.0 Synthesis of arecoline hydrogen bromide 
 
Importantly, all three authors used potassium borohydride to selectively 
reduce the pyridine ring to yield the desired allylic ester.  In the first instance, 
Panouse and Kinoshita carried out this reduction in methanol with 32-36% yield.40   
Kozello improved on their original strategy by carrying out the reduction in water 
under a layer of benzene with an improved yield of 42%.40  
Since the work by Kozello et al. on the synthesis of arecoline numerous 
investigations have been carried out to evolve from the natural product to an M1 
selective agonist.  It is the work that is summarised below which gives an overview of 
the origin of the target molecule to date. 
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Some of the first modifications to arecoline were carried out by Sauerberg et 
al. in 1992, with investigations into the synthesis and structure-activity relationship 
(SAR) of 3-(1,2,5-thiadiazoyl)-1,2,5,6-tetrahydro-1-methylpyridines.41  A wide variety 
of molecules were synthesised and evaluated with SAR primary measure being IC50 
(nM) of receptor binding in rat brain membrane.  The most promising molecules and 
their syntheses are summarised in Scheme 2.01.  As well as the molecules shown in 
Figure 2.03, furan and oxazole rings were also investigated.  However it was found 
this resulted in a decrease in affinity for the M1 receptor. 
 
Scheme 2.01 Summary of synthetic strategy of alkoxy/alkylthio thiadazole 
derivatives of arecoline41 
 
A variety of alkyl substituents were investigated for R, and it was found that 
unbranched, short alkyl substituents gave the best selectivity for M1 receptor.  Both 
types of molecule demonstrated promising selectivity with minor peripheral side 
effects in rat and guinea pig models, making them potential candidates for the 
treatment of AD.   
At approximately the same time, work was being carried out by Ward et al. on 
behalf of Lilly Pharmaceuticals into developing arecoline in a very similar manner to 
Sauerberg.42  The three molecule models of interest are given in Figure 2.01, with 
their general synthetic strategy in Scheme 2.02. 
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Figure 2.01 Synthetic models for M1 receptor agonist
42 
 
 
Scheme 2.02 General synthetic strategy for synthesis of l-Methyl-l,2,5,6-
tetrahydropyridyl-1,2,5-thiadiazolee, -pyrazines, and -l,2,5-oxadiazoles42 
 
By comparison of the work carried out by Sauerberg and Ward we see distinct 
similarities in the backbone of the molecule.  Both series of molecules include 1-
methyl-1,2,5,6-tetrahydro pyridine rings, as does arecoline.  This suggests an 
important motif to the selectivity of the molecules for M1 receptor.  In addition to this, 
both papers focused on the use of heterocyclic ring systems in place of the ester of 
arecoline.   
Their respective approaches to the synthesis of such molecules are 
somewhat different. Sauerberg opted for a synthetic strategy more in line with the 
original synthesis of arecoline whereby they started from a pyridine derived molecule 
and installed the desired heterocyclic ring system plus any required functionality 
followed by N-methylation and regioselective reduction of the pyridine ring.  By 
contrast Ward opted for a synthesis that involves a functionalisation of the alcohol at 
the piperidine ring to yield the desired alkene before introducing the desired 
functionality on the heterocyclic ring.   
  The binding affinities were assessed by the displacement of radiolabelled 
compounds already occupying the muscarinic receptor.  This approach is perhaps 
somewhat problematic given that it gives no insight into metabolism of the target 
molecule, bioavailability or additional binding interactions beyond the target receptor.  
However this does demonstrate the use of such radiolabelled compounds with 
respect to drug design that is convenient to measure in vivo affinity.  To address this 
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problem we carried out a molecular modelling investigation into the muscarinic 
receptor discussed further in chapter three. 
More recently, the development of such molecules has led to derivatisation 
with morpholine.  Morpholine is found in many naturally occurring products and 
drugs but is often restricted in its use as it is often accessed via amino alcohols or 
amino epoxides.43  Introduction of chirality into morpholine derived compounds is 
often achieved by starting from enantiopure amino alcohols, frequently from the 
naturally occurring chiral pool.  As such this puts a limitation on the number of 
accessible morpholine compounds.   
As a result, morpholine is more frequently used as a base or N-alkylating 
agent.  C-functionalised morpholine is much less explored but offers great potential 
given its frequent occurrence in nature.43  
With this in mind more recent publications of selective M1 agonists 
incorporating C-functionalised morpholine have been put forward.  The first 
generation of such a compound was synthesised by Kumar et al. in 2007.44 The 
synthesis of the arecoline derived compound was achieved in nine steps in good 
yield (Scheme 2.03) 
 
Reagents: (i) HBr, acetic acid (ii) N-benzylaminoethanol, K2CO2, DMF (iii) NaBH4, MeOH (iv) H2SO4, 
reflux (v) a) 10% Pd-C, ammonium formate, MeOH, reflux b) (Boc)2O, THF, K2CO2 (vi) a) MeI, 
acetone b) NaBH4, MeOH (vii) HCl, MeOH 
Scheme 2.03 Synthesis 2-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)morpholine44 
 
This general synthesis gives access to C-functionalised morpholine 
substituted arecoline derived compounds with an overall yield of 36% from the 
starting acetyl pyridine to the final product.  This compound was evaluated as a 
potent, selective M1 agonist.
44 This synthetic strategy offers possible further 
derivitisation at the secondary amine of the morpholine ring that were subsequently 
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synthesised and evaluated as described below.  It is worth noting the similarities to 
the original synthesis of arecoline with the final steps including N-methylation and 
subsequent reduction with sodium borohydride.  While the use of potassium 
borohydride was described in the original synthesis, sodium borohydride was shown 
to give an improved yield in this case. 
To further derivatise the secondary amine this work was continued with a 
publication by the same group in 2008.45  The work focused on the synthesis of 
sulfonyl derivatives with a variety of electron donating and withdrawing properties.  
The general approach for the synthesis follows that described in Figure 2.06 with 
subsequent derivatisation described in Scheme 2.04. 
 
Scheme 2.04 Synthetic approach to sulfonyl derivatives of morpholino arecoline45 
 
The 4-substituted aromatic sulfonyl substituents (Figure 2.02) resulted in a 50 
to 80 fold increase in M1 receptor binding when compared to arecoline.  
 
Figure 2.02 M1 selective 4-substituted 2-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-4-
(phenylsulfonyl)morpholine derivatives 
 
Interestingly, the effects of electron withdrawing substituents were 
investigated by Kumar.  It was found that nitro-substituents at ortho and para 
positions notably decreased the affinity of the compound to M1 receptor as compared 
to those examples given in Figure 2.02.  This decrease in affinity was observed to a 
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lesser extent in the meta position, due to the less withdrawing effect at the meta 
position. 
One of the most important findings was that the toxicity of all the compounds 
synthesised and evaluated by Kumar et al. was low with no visible side effects 
observed in rat brain models.45  By contrast to some of the earlier work discussed 
previously, this represents a promising development towards a highly selective M1 
receptor agonist. 
In a similar vein Malviya et al. carried out further investigations into the 
synthesis and evaluation of N-arylthiourea morpholine arecoline derivatives.46  Again 
the synthesis followed that given in Scheme 2.03 followed by derivatisation via 
Scheme 2.05. 
 
Scheme 2.05 Synthetic approach to arylthiourea derivatives of morpholino 
arecoline46 
 
Again a variety of compounds were synthesised and evaluated in the same 
fashion as the work previously discussed showing a several fold increase in affinity 
as compared to arecoline.46  The best examples from this investigation are given in 
Figure 2.03.  No direct comparison is given for the respective affinities between the 
sulfonyl and arylthiourea derivatives; however from the detailed IC50 values the 
sulfonyl derivatives show marginally improved affinity.  
 
Figure 2.03 M1 selective 4-substituted 2-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-N-
phenylmorpholine-4-carbothioamide46 
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In more recent publications Sadashiva et al. proposed the synthesis and 
biological evaluation of N-alkyl/aryl thiazolidinone arecoline derivatives.  This 
constitutes a move back to much earlier  examples of arecoline derived compounds 
similar to that of Sauerberg previously described.41  
A novel synthetic strategy to access N-alkyl/aryl thiazolidinone arecoline 
derivatives was proposed from the same starting material as Sauerberg.  3-Pyridine 
carboxaldehyde was reacted with a variety of different amines in the presence of the 
catalyst γ-ferrite (Scheme 2.06).47  
 
Scheme 2.06 Synthetic strategy to N-substituted thiazolidinone derivatives 
 
The compounds synthesised with the reported highest affinity are given in 
Figure 2.04.  All the compounds synthesised were subjected to the same biological 
evaluation that was carried out by Kumar et al. and Malviya et al.47  
 
Figure 2.04 M1 selective N-substituted 2-(1-methyl-1,2,5,6-tetrahydropyridin-3-
yl)thiazolidin-4-one derivatives 
 
It was noteworthy that as with the morpholine substituted compounds no 
cholinergic toxicity was observed at comparable doses.47 However, the measured 
affinity for M1 receptor was poor by comparison to the morpholine arecoline 
derivatives already discussed.  More in depth in vitro/vivo studies need to be carried 
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out to strengthen the suitability of this class of molecules as a selective therapeutic 
M1 receptor agonist. 
The most recent work carried out by Malviya et al. in 2009 built on their 
previous publications and looked to synthesise and evaluate novel N-aryl 
carboxamide substituted morpholine arecoline derived compounds.2 The results 
suggest that para substituted methyl aromatic amide moieties (Figure 2.05) exhibit 
selectivity towards M1 receptor with anti-dementia activity. 
 
Figure 2.05 Structure of (2-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)morpholino)(p-
tolyl)methanone2 
 
The synthesis is again based on the strategy developed in the previous 
publication (Scheme 2.03) followed by reaction with the corresponding acid chloride 
(Scheme 2.07). 
 
Scheme 2.07 Synthesis of (2-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)morpholino)(p-
tolyl)methanone2 
 
This reaction has been common to all of the syntheses by Malviya et al. and 
Kumar et al. of a variety of substituted morpholine arecoline derived compounds.   
From studies performed in vitro it was noted substitution at the para position 
of the aromatic ring is important for M1 receptor activity.  The same molecule with no 
para substituent was evaluated, and it was found that the affinity and potency of the 
compound decreased by several-fold compared to those compounds with a para 
substituent.2 A number of substituents were investigated (Figure 2.06) and subjected 
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to in vitro affinity studies towards M1 receptor of male Wistar rat cortex synaptosomal 
membrane.  The results of these studies are given in Table 2.01.2 This was the 
assessment of affinity used by all publications discussed.   
 
Figure 2.06 Analogues of carboxamide morpholino arecoline derived M1 receptor 
agonist 
Compound: Ki (µM) IC50 (µM) 
a 19 ± 3.22 76 ± 5.51 
b 0.42 ± 0.06 1.6 ± 0.13 
c 1.3 ± 0.08 4 ± 1.50 
d 126 ± 13.83 618 ± 20.35 
e 48 ± 7.32 142 ± 11.14 
f 65 ± 6.12 215 ± 13.50 
arecoline 88 ± 11.25 460 ± 18.18 
 
Table 2.01 In vitro affinity assay of carboxamide substituted morpholino arecoline 
derivatives towards M1 receptor of male Wistar rat cortexsynaptosomal membrane. 
 
As with previous examples none of these compounds exhibited toxic 
cholinergic activity with respect to visible side effects.   
Compound b emerged as a promising derivative with anti-dementia activity.  It 
is this derivative that forms the basis of our investigation to incorporate a 
radionuclide for the purposes of PET imaging.  When considering a strategy towards 
a PET contrast agent it was important for us to consider where to incorporate the 
radionuclide since this will have significant bearing on the design of the synthesis.  
As discussed previously it is important to incorporate the radionuclide at the end of 
N
O
N
O R
R =
NO2
NO2
NO2
a b c d e f
Cl
 
22 
the synthesis, termed the “hot step”, to allow chemical incorporation and purification 
within the half life of the radionuclide. 
In this investigation we wanted to not only gain experience with the synthetic 
challenges of PET contrast agents, but also demonstrate a novel method for the 
incorporation of a radionuclide.  With this in mind and combined with the appeal of 
offering a synthesis that could be applied to a variety of compounds within this class 
of M1 receptor agonists, compound 1 was selected as the target molecule for this 
investigation (Figure 2.07). 
 
Figure 2.07 Proposed PET contrast agent towards M1 receptor 
 
Incorporation of the radionuclide at the N-methyl of the tetrahydropyridine ring 
is convenient in this case as this moiety is common to all M1 receptor agonists 
discussed in this chapter.  Conveniently, the original synthesis of this molecule would 
allow the incorporation of a radionuclide provided that the final N-methylation and 
regioselective reduction can be carried out in a short time frame of approximately 10 
minutes (Scheme 2.03, step (iv)).   
In the synthesis proposed by Malviya et al. the N-methylation and reduction 
are not detailed with respect to time taken for the reaction to complete.2 However 
this chemistry has been carried out on numerous examples and proceeds in the 
order of 2 hours to carry out an N-methylation and 3 hours for the subsequent 
reduction.  It was our challenge to condense this chemistry into 10 minutes. 
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2.1 TOWARDS THE SYNTHESIS OF (2-(1-METHYL-1,2,5,6-
TETRAHYDROPYRIN-3-YL)MORPHOLINO)(P-TOLYL)METHANONE (1) 
Before embarking on the synthesis of the target molecule (Figure 2.06) we felt 
it was necessary to ascertain whether the 10 minute time scale was realistic on 
simple models.  We chose pyridine as a simple model (Scheme 2.08) to demonstrate 
the necessary chemistry and satisfy ourselves that it was worthwhile embarking on 
the synthesis of 1.  
 
Scheme 2.08 Synthesis of 1-methyl-1,2,3,6-tetrahydropyridine 
 
Initially our approach involved the synthesis of 2 and 3 individually to attempt 
each step in a short time scale.  In the synthesis described by Malviya et al. the N-
methylation was carried out in acetone.2 We chose to carry out this reaction in 
methanol with a view that these steps could eventually be carried out in one pot or in 
flow.  The reactions were carried out at varying temperatures (Table 2.02). 
Time 
(min) 
Temperature 
(oC) 
Concentration 
of pyridine 
(mol) 
Concentration of 
MeI (mol) 
Yield of 2 (% from 
pyridine) 
120 25 0.06 0.05 62% 
3 30 0.06 0.05 nil 
3 35 0.06 0.05 nil 
3 40 0.06 0.05 4% 
3 45 0.06 0.05 7% 
3 50 0.06 0.05 8% 
3 55 0.06 0.05 10% 
3 60 0.06 0.05 14% 
3 reflux 0.06 0.05 16% 
 
Table 2.02 Kinetic studies for N-methylation of pyridine 
 
 
 
24 
The N-methylation of pyridine was followed by NMR, sampled every two 
minutes for an eight minute period (Figure 2.08).  The traces show clean conversion 
to the N-methyl pyridinium salt with no side reaction occurring.  
 
Figure 2.08 N-methylation of pyridine followed by NMR 
 
While the N-methylation was successful with a clear increase in yield with 
increased temperature to a yield of 16% at reflux to a level that we felt was 
acceptable for our first attempt, the subsequent reduction product 3 could not be 
successfully isolated.  This is possibly due to a low boiling point similar to that of 
methanol.  Since we had satisfied ourselves that the N-methylation progresses 
quickly, we turned to a less volatile model to improve the yield and prove that the 
borohydride reduction could be carried out quickly.  We decided to move to 
isoquinoline to model the same chemistry; this offers the distinct advantage of being 
able to follow the reaction easily via thin layer chromatography (TLC) (Scheme 2.09). 
 
Scheme 2.09 Synthesis of 2-methyl-1,2,3,4-tetrahydroisoquinoline 
 
This strategy proved successful with the N-methylation of isoquinoline yielding 
4 in 85%.  The subsequent reduction also proved successful with the reaction 
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proceeding initially in 20 minutes to yield 5 in 52% from 4.  Having successfully 
carried out the reaction with isolation of 5 we were able to repeat the step at reflux 
and quenching after 8 minutes yielding 5 in 27% from 4.  In light of these results we 
felt it was worthwhile proceeding onto a synthesis of 1. 
Our strategy was to offer a synthesis that primarily would allow the successful 
incorporation of a radionuclide but also an alternative synthetic route to allow access 
to a variety of C-functionalised morpholine derivatives if so required.  Our first 
generation retrosynthetic analysis (RSA) of 1 is shown in Scheme 2.10. 
 
Scheme 2.10 First generation RSA towards 1 
 
In the first dissection of the C-C bond between the morpholine and tetrahydro 
pyridine rings (i) we hoped to achieve this step via a Heck coupling between the 
alkene of the morpholine ring and 3-bromopyridine.  The N-methylation can be 
carried out as previously discussed via treatment with iodomethane and sodium 
borohydride reduction (iii).  Finally, the amide bond can be formed via reaction with 
4-methylbenzoyl chloride.   
This synthetic strategy offers a novel route to 1 from commercially available 
starting materials in six synthetic steps (Scheme 2.11). 
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Reagents: (i) TEA, DCM (ii) NBS, HCOOH, MeOH (iii) TfOH, CHCl3 (iv) Heck coupling, Pd catalyst, 
base (v) MeI, MeOH (vi) NaBH4, MeOH  
Scheme 2.11 Synthetic strategy towards 1 
 
 Initially we had some success with this strategy with step (i) giving a good 
yield.  Unfortunately step (ii) was somewhat problematic with no product isolated 
from the reaction mixture.  The basis of the step was derived from previous work 
carried out by Liebner et al. into the synthesis of a variety of morpholine analogues.48  
This chemistry, while not identical to our application, had proved very successful in 
the original publication and thus we felt confident it would work in this case.  
However, having carried out numerous repetitions of this reaction with a variety of 
conditions, it was eventually decided to abandon this strategy to synthesise 1. 
 Our second generation synthetic strategy involved a novel approach to PET 
contrast agent 1.  The RSA is given in Figure 2.12. 
 
Figure 2.12 Second generation RSA towards 1 
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 There are distinct similarities between this revised RSA and our first attempt.  
Primarily, the incorporation of the radionuclide remains unchanged but the formation 
of the amide bond is moved later in the synthesis.  To form the C-substituted 
morpholine ring we envisaged a cyclisation between an aminoalcohol and 
bromoacetyl bromide.  The inspiration behind this step was taken from work carried 
out by Zindell et al. in 2006 into the synthesis of morpholine-derived CB2 agonists.49 
The synthetic strategy is given in Scheme 2.13. 
 
 Reagents: (i) NCS, HCl(g), AcOH (ii) NaBH4, MeOH/H2O (iii) 30% NH4OH/MeOH then 37% 
HCl/EtOH (iv) a) bromoacetyl bromide, EtOAc, NaHCO3/H2O b) KO
t
Bu, 
t
BuOH, c) LAH, THF (v) 4-
methylbenzoyl chloride, TEA, DCM (vi) MeI, MeOH (vii) NaBH4, MeOH  
Scheme 2.13 Second generation synthetic strategy towards 1 
 
 Our second strategy proved much more successful with the initial steps 
progressing as described by Perrone et al. with respect to the synthesis of 3-
chloroacetylpyridine, which was isolated as the hydrochloride salt.  We were pleased 
to report an improved yield of 86% over step (i) as compared to 76% previously 
published by Perrone et al.50  The yield of this reaction seems to be dependent on 
the volume of HCl gas introduced to the acetic acid.  Initially we introduced HCl gas 
over a period of one hour as a benchmark based on the work carried out by 
Duquette et al. who reported a yield of 83% for the same reaction.51  This did indeed 
give good yield in the order of 79%.  However, we looked to improve on this by 
introducing HCl gas over an extended period of time.  Introduction of HCl gas below 
the surface of the acetic acid over a period of two hours at 16 oC offered the 
optimum yield with 3-chloroacetyl pyridine hydrochloride crystallising out of solution 
in approx. 4 hours.   
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 The following sodium borohydride reduction progressed as expected with 
90% yield as a yellow oil.  Purification of the crude oil by column chromatography 
gave the pure alcohol in 58% yield.  Step (iii) proved initially problematic with respect 
to the isolation and purification of the amino alcohol and thus was taken as a crude 
mixture directly onto step (iv).   
As previously stated this cyclisation was inspired by the work carried out by 
Zindell et al. with their investigation into CB2 selective agonists.49  At our current 
point in the synthesis we are experiencing difficulties with the purification of the 
cyclised compound B, Figure 2.14. 
 
Scheme 2.14 Suggested reaction intermediates step (iv), Scheme 2.13 
 
It is probable that the reaction proceeds in the first instance to form the amide 
of intermediate A (Scheme 2.14) under Schotten-Baumann conditions.  The 
cyclisation to yield intermediate B is based-induced by deprotonation of the alcohol 
followed by nucleophilic substitution to displace bromide.  
   As discussed later, we have ceased our attempts to synthesise 1 in favour of 
new target compounds 2 and 3, while access to C-functionalised moieties are 
valuable, the priority of this investigation is to demonstrate the “hot steps” for 
radionuclide insertion in a fully synthesised M1 muscarinic receptor compound.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
3.0 MOLECULAR MODELLING STUDIES 
 Drug design is an iterative process which begins with the identification of a 
compound that displays an interesting biological profile and ends when both the 
activity profile and the chemical synthesis of the new chemical entity are optimized. 
Traditional approaches to drug discovery rely on a step-wise synthesis and 
screening program for large numbers of compounds to optimize activity profiles. 
Over the past ten to twenty years, scientists have used computer models of new 
chemical compounds to help define activity profiles, geometries and reactivities. 
Over the past few years, advances in the development of new mathematical 
models which describe chemical phenomena and development of more intuitive 
program interfaces coupled with the availability of faster, smaller and affordable 
computer hardware have provided experimental scientists with a new set of 
computational tools. These tools are being successfully used, in conjunction with 
traditional research techniques, to examine the structural properties of existing 
compounds, develop and quantify a hypothesis which relates these properties to 
observed activity. 
There are many software packages available to carry out molecular 
modelling, each varying in complexity and cost.  In broad terms the selection of 
software packages can be divided into classical or quantum.  The classical (or 
Newtonian) modelling attempts to describe a model by considering the nucleus and 
electrons collectively; atoms are assigned with associated mass and charge.  Within 
a molecular model, the chemical bonds are visualised as springs considering Van 
der Waals forces.  Electrostatic interactions are assigned based on Coulomb’s law.  
In contrast, quantum software packages consider electrons explicitly, the benefit of 
classical molecular modelling is the level of complexity is reduced, thus more atoms 
can be considered in the model.  Given the field of molecular mechanics is 
extensive, for the purposes of this discussion we will consider only classical 
molecular modelling and those techniques used within this investigation. 
 
ENERGY MINIMISATIONS 
 As stated previously, in classical molecular modelling, chemical bonds are 
visualised as dynamic springs.  When carrying out energy minimisations of a given 
molecule the software looks to find an energy minimum that would be representative 
of a molecules structure.  The importance of determining a suitable starting 
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conformation cannot be underestimated to determine the true energy minimum for a 
given structure.  Failure to obtain a suitable starting conformer could lead to 
minimisation into a local minimum where, which may not be the global minimum 
energy conformer.  For this investigation we will carry out minimisations using a 
Fletcher-Powell method where by the force field constant (second derivative 
representative on Figure 3.0) is set to a constant and each newly generated 
conformer is compared to the previous derivative, the iterative process looks to 
achieve the desired force constant (Figure 3.0). 
 
Figure 3.0 Plot of energy versus atomic radii  
 
The major disadvantage of this process is the computational time taken, 
however, for small organic molecules the target force constant can generally be 
achieved in <500 iterations (approx. 30 minutes). 
 
CONFORMATIONAL ANALYSIS 
Once an energy minimum has been established for a given molecule, it is 
important to consider a range of possible conformers that could be adopted.  
Conformational analysis can be performed by defining rotatable bonds within a 
molecule at 30-360o increments.  The computer software compiles a spreadsheet of 
conformers from which the energy can be calculated, and in this case, we can carry 
forward the lowest energy conformers to the docking experiment.  Again, the major 
limitation with conformational analysis is the limitation of computing power available.  
Clearly for increasing numbers of rotatable bonds the number of potential 
conformers increases exponentially.  As a result, it is important to make reasonable 
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assumptions about the degrees of freedom around a given bond.  For example, it 
would be unrealistic to allow the software to assess each rotatable bond in 30o 
increments when 90o increments would lead to the same energy conformer.   
 
COMFA ANALYSIS 
 CoMFA (Comparative Molecular Field Analysis) is a 3D QSAR technique 
based on data from known active molecules. CoMFA can be applied when the 3D 
structure of the target receptor is unknown. To apply CoMFA, all that is needed are 
the activities and the 3D structures of the molecules.  The aim of CoMFA is to 
identify a correlation between the biological activity of a set of molecules and their 
3D shape, assessing their electrostatic and hydrogen bonding characteristics. 
 The process involves overlaying common structures and placing in a 3D grid 
where probe atoms are used to assess the steric and electrostatic energy (Figure 
3.01), each molecule is assessed and a score is generated.  These data are 
validated by the process of PLS (partial least squares) initially using cross validated 
PLS analysis, whereby one value is left out and remaining data are used in the 
model.  This analysis is used to determine the optimal number of components to 
subsequently carry out non-cross validated PLS analysis.  It is important to note the 
value of R2 for the non-cross validated PLS analysis as this gives an indication of the 
predictive power of the model. 
 
 
 
Figure 3.01 Example of overlaid structures in 3D grid 
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PROTEIN HOMOLOGY MODELLING 
 The challenge of protein modelling is one that has been addressed for many 
years; X-ray crystallography still remains the most powerful tool for the determination 
of biological macromolecule structure.  However, in recent years 1H NMR 
spectroscopy combined with computational modelling has been used to determine 
the structure of proteins and peptides.  At present this technique is limited to use on 
small proteins given the complexity of these macromolecules and NMR techniques 
typically offer lower resolution than an X-ray diffraction structure. 
 There is great interest in developing techniques to model protein structures 
from their amino acid sequence, given that literally thousands of protein sequences 
are known and yet only hundreds of complete structures have been determined.  
However, the reasons how and why a protein folds are two crucial questions that 
need to be addressed before a satisfactory prediction of secondary and tertiary 
structures can be made.  Furthermore, assuming proteins fold at random, the 
computational resources required to assess every possible structure and 
conformational state with multiple energy minima is intangible.   
 Protein homology modelling has thus far proved to be the most successful 
method for predicting a tertiary structure.  The process develops a model of an 
unknown protein structure from a known structure of homologous protein.  The 
success of the procedure is based on the fact that protein secondary structures are 
well conserved between homologous proteins. 
 In the first instance, the two amino acid sequences are compared to identify 
areas of agreement.  Particularly, we look for agreement between the two primary 
structures at critical areas in the sequence, namely, the active site, helices and β 
sheets.  The primary sequence can be modified if required to ensure good alignment 
between the two sequences, however, amino acid substitutions are generally not 
extensive since protein function is not dependant on one residue and mutations on 
the exterior of the protein do not inhibit protein function. 
 Once a suitable model has been identified, the unknown protein structure is 
superimposed on the one that is known and by computational analysis the model is 
generated.  It is worth noting that any suggested model should be scrupulously 
examined for key features such as di-sulfide bridges to ensure good agreement with 
that of the original model.   
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3.1 RESULTS AND DISCUSSION 
 As part of our particular interest in M1 muscarinic receptor we sought to 
construct a model of the M1 muscarinic receptor and perform docking studies with a 
range of compounds based on those evaluated in vitro by Augelli-Szafran et al.3 By 
collaboration within the Interreg group we were able to gain access to the necessary 
software working under the supervision of Prof. R. Bureau (CERMN, Uni Caen).  
Within this collaboration our aim was to carry out protein modelling, docking studies 
and gain familiarity with the Tripos-Sybyl X software package that had currently not 
been used to carry out such an investigation.  We aim to identify key residues within 
the M1 muscarinic receptor that will lead to a more targeted approach to the design 
of M1 muscarinic receptor antagonists.  Furthermore, given the advances that have 
been made in the field of molecular mechanics in the past 5 years, we look to 
validate our data against in vitro data obtained by Augelli-Szafran et al.3 
In the first instance, we identified a range of analogues, from those 
synthesised by Augelli-Szafran to represent the range of binding results, previously 
determined, on which we could carry out the modelling.  These analogues had a 
range of IC50 values varying from nano to micro molar, identified in Table 3.0 with 
their respective IC50 value towards the M1 muscarinic receptor.  It is important to 
note that in the original publication by Augelli-Szafran, et al.  No consideration was 
given to the absolute stereochemistry between motifs R and S (Figure 3.02); 
however for our purposes we modelled both the R and S forms to determine any 
discrepancies in predicted binding affinities between the two isomers. 
Once we identified these range of analogues we set about modelling our 
database using the program Sybyl X.  This process involved the construction of each 
analogue by overlaying each analogue with a known crystal structure of similar 
pharmacophore, namely the di-substituted tetrahydropyridine ring.  These analogues 
were then subject to minimisation techniques to identify local energy minima using a 
Powell method with a gradient termination value of 0.05 kcal/mol.  The Tripos force 
field was considered given we are considering small organic molecules, no 
consideration was given to charge.   
The subsequent energy minimised analogues were processed to generate a 
range of conformers (in the order of 100-200 conformers) using a systematic search.  
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This process involves identifying rotational bonds within each analogue and 
specifying the degrees of freedom around each bond.  For example the degree of 
rotation around the ester is 180 degrees, whereas the degree of freedom around C-
C bond is 360 degrees in 30 degree increments.  This is a limitation of the software 
as it will only assess rotational bonds in 30 degree increments.  Another important 
consideration when undertaking any molecular modelling experiment is to assess the 
computational capacity available given this will determine the range of conformers 
that can be processed.  In this case we felt anything up to 200 conformers of each 
analogue would be a good representation to allow successful analysis.  For this 
selection of conformers the relative conformational energy was calculated.  One 
such example is given in Figure 3.03. 
 
Figure 3.02 Structural motifs of pharmacophore 
Compound Motif Isomer R IC50 (nM) 
4 B R (CH2)5CH3 27.3 
5 B S (CH2)5CH3 27.3 
6 A - CH2C6H11 14.5 
7 A - C6H11 18.1 
8 B R C6H11 16.9 
9 B S C6H11 16.9 
10 A - (CH2)2Ph 9.6 
11 A - CH2CH(CH3)2 120.5 
12 B R CH2CH(CH3)2 128 
13 B S CH2CH(CH3)2 128 
14 A - (CH2)9CH3 106.1 
15 B R (CH2)2Ph-p-OCH3 159 
16 B S (CH2)2Ph-p-OCH3 159 
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17 A - CH3 2308 
18 B R CH3 33117 
19 B S CH3 33117 
20 A - Ph 1819 
21 A - CH2CH3 888 
22 A - (CH2)2Ph-p-OCH3 1941 
 
Table 3.0 Range of analogues identified for modelling study 
 
Figure 3.03 Lowest energy state of compound 10 following conformational analysis 
 
The example given in Figure 3.03 is a typical result of the conformational 
analysis performed with an energetically stable conformation adopted as a result of 
structural characteristics.  Namely, this class of molecules adopt a folded 
conformation to stabilise Van der Waals forces between the R group and the 
substituted aromatic of the tetrahydropyridine ring.  In Figure 3.03 we see the two 
aromatic rings arranging themselves in as close to a stacked position as 
conformationally possible given the defined bond rotations.  In other alkyl R 
substituted examples this folding is mirrored, this may not be truly representative of 
the conformation the substrate would adopt in vivo, but is a reasonable estimation 
given hydrophobic nature of the alkyl/aromatic groups in aqueous solution.  
Unsurprisingly, the N-ethyl group adopts an equatorial position on the twist-boat of 
the tetrahydropyridine ring, minimising 1-3 steric interactions. 
Figure 3.04 shows an example of compounds 18 and 19.  When compared to 
the compound 10 in Figure 3.03 we see structural similarities with respect to the 
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folding of the R group across the aromatic ring, but also structural differences in that 
the tetrahydropyridine ring is flipped.  However, the N-ethyl maintains its equatorial 
position for the reason previously stated. 
 
Figure 3.04 Lowest energy state of compounds 18 (right) and 19 (left) following 
conformational analysis 
From the database of conformers, the energy for each conformer was 
calculated and the lowest energy conformer selected to take forward to the docking 
study (Appendix 1).  The docked conformers were subject to COMFA analysis and 
the results treated by PLS statistical analysis to determine the validity of the results 
(Figure 3.06).  The results from PLS analysis carrying out non-cross validation 
across 19 components yielded a value of R2 = 0.457.  This is regarded as a good 
correlation between predicted and experimental binding affinity (R2 > 0.5 – excellent 
correlation). 
 
Figure 3.05 Identified pharmacophore for COMFA analysis 
 
Compound Motif Isomer COMFA Score IC50 (nM) 
4 B R 81 27.3 
5 B S 82 27.3 
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6 A - 80 14.5 
7 A - 78 18.1 
8 B R 77 16.9 
9 B S 75 16.9 
10 A - 82 9.6 
11 A - 73 120.5 
12 B R 67 128 
13 B S 68 128 
14 A - 94 106.1 
15 B R 86 159 
16 B S 83 159 
17 A - 61 2308 
18 B R 62 33117 
19 B S 60 33117 
20 A - 71 1819 
21 A - 65 888 
22 A - 83 1941 
 
Table 3.01 Summary of results from COMFA analysis 
 
Figure 3.06 Plot of experimentally determined IC50 binding affinity versus predicted 
score (COMFA analysis) (R2 = 0.42) 
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With an extensive database of conformers in hand we set about modelling the 
M1 muscarinic receptor to carry out the docking experiment.  The crystal structure of 
the M1 muscarinic receptor has not been published to date.  As a result we had to 
construct our model based on known crystal structures of similar proteins.  By 
sequential analysis, using information from the protein data bank we found a 95% 
agreement in the primary structure of M1 muscarinic and β2 adrenergic receptor.  
Following sequence alignment (Appendix 2) between the human M1 muscarinic and 
β2 adrenergic receptor we observe good agreement on all 7 helices, as a result we 
were able to superimpose the M1 muscarinic receptor primary sequence onto the 
crystal structure of antagonist bound human β2 adrenergic receptor (Figure 3.07) to 
yield the predicted structure of M1 muscarinic receptor (Figure 3.08).  On close 
examination we see good correlation in the secondary structure and importantly in 
tertiary structure with disulfide bridges conserved between models. 
 
Figure 3.07 Antagonist bound β2 adrenergic receptor 
Note the presence of additional structure positioned intracellular to the 
receptor (bottom of picture), this was necessary to obtain a crystal structure of β2 
adrenergic receptor and thus must be included in the model of M1 muscarinic 
receptor.  This is an acceptable modification as it does not impede the ligands 
binding which occurs on the extracellular face of the receptor.  With a model in hand 
we turned our attention to carrying out the docking experiment of our conformers 
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with the M1 muscarinic receptor.  The results for the most tightly bound conformer of 
each analogue is summarised in Table 3.02. 
 
Figure 3.08 Predicted M1 muscarinic receptor tertiary structure 
Compound Motif Isomer COMFA Score IC50 (nM) Binding Score* 
4 B R 81 27.3 5.04 
5 B S 82 27.3 4.34 
6 A - 80 14.5 6.84 
7 A - 78 18.1 4.46 
8 B R 77 16.9 -‡ 
9 B S 75 16.9 -‡ 
10 A - 82 9.6 5.12 
11 A - 73 120.5 4.53 
12 B R 67 128 4.23 
13 B S 68 128 3.61 
14 A - 94 106.1 5.45 
15 B R 86 159 3.81 
16 B S 83 159 5.64 
17 A - 61 2308 2.48 
18 B R 62 33117 3.53 
19 B S 60 33117 2.65 
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20 A - 71 1819 3.94 
21 A - 65 888 3.93 
22 A - 83 1941 4.88 
*Score generated from Surflex-Dock (SFXC) methodology ‡Compounds 8 and 9 
were rejected from the docking study due to steric clash with protein residue. 
Table 3.02 Summary of results from docking experiment 
 
Figure 3.09 M1muscarinic receptor showing protomol for docking study (Appendix 2) 
 
Thus far we have determined that electrostatic interactions between the 
quaternary amine and aspartic acid (ASP 105) combined with hydrogen bonding 
between the proton of the quaternary amine and tyrosine (TYR 404) are responsible 
for the binding of our analogues to the M1 receptor.  There are hydrophobic pockets 
for the dihydropyridine substituted aromatic and the various R functionalities that are 
all alkyl or aromatic.   
The binding position of the dihydropyridine ring and the substituted aromatic 
are well conserved across the analogues assessed.  However, while the R groups 
adopt similar positions in the hydrophobic pocket, their relative size appears to have 
a direct impact on the hydrogen bonding and electrostatic distance between the 
quaternary amine and the receptor.  This would account for the variation in IC50 
values observed in vitro, given there is correlation between predicted binding affinity 
and experimentally determined affinity.  A plot of the binding score versus in vitro 
 (Figure 3.11) shows moderate agreement between the computationally determined 
binding score and in vitro 
agreement is likely in part due to our modelling of both the R and S isomers since 
their respective binding scores
values were determined with a racemic mixture of the isomers when in fact we 
predict, unsurprisingly, their binding interactions are very different.
In summary, we have constructed a suitable model of M1 muscarinic receptor 
and through docking studies have shown good agreement with 
Furthermore, we have identified key structural features that are crucial for M1 
binding that offer new insight to further develop M1 selective compounds.
Figure 3.10 Compound 7 docked into receptor 
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IC50 values with R
2 = 0.310.  The reason for the lack of 
 are plotted against the same IC50 value.  These IC
 
 
– hydrogen bonding and electrostatic 
interactions shown 
50 
in vitro data.  
 
 
 
43 
 
Figure 3.11 Plot of experimentally determined IC50 binding affinity versus predicted 
score (docking analysis) (R2 = 0.310) 
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4.0 TOWARDS THE SYNTHESIS OF 2 AND 3 
As previously stated this work has been carried out in collaboration with Dr. 
Cécile Perrio (Laboratoire de Développements Méthodologiques en TEP, Cyceron) 
who has offered invaluable advice with respect to the current methodologies 
employed in the synthesis of PET contrast agents.  After reviewing our work in the 
synthesis of 1, we were given the advice that a M1 muscarinic receptor antagonist 
would be of greater value than the agonist.   
 Given our work to date has looked to employ the incorporation of 11C 
radiolabel at an N-alkyl position we propose to find a suitable M1 muscarinic receptor 
antagonist that could follow in this theme.  After an extensive literature search we 
were pleased to identify our second target molecule (Figure 4.0) from the work 
carried out by Augelli-Szafran et al in 1999.3  This was an attractive publication as it 
details the synthesis of a wide range of molecules that had been assessed in vitro for 
SAR for all 5 muscarinic receptor sub-types.3 
 
Figure 4.0 1, 4-Disubstituted tetrahydropyridine motifs 
 
In the same way as our previous work, the two compounds A and B are 
synthesised from pyridine derived starting materials and the N-ethyl group 
introduced at the end of the synthesis followed by NaBH4 reduction (Scheme 4.0). 
 
Scheme 4.0 N-ethylation and NaBH4 reduction to yield A and B 
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This compliments our work to date with the added synthetic challenge of yielding two 
regio-isomers from the reduction step.   
 We quickly identified a suitable target compound that had a high affinity (nM) 
and specificity for M1 muscarinic receptor (Figure 4.01).   
 
Figure 4.01 Target precursor prior to radiolabel introduction 
 
We looked to synthesise a good quantity of the precursor (Figure 4.01) that 
could then be tested to develop the rapid reactions to incorporate a suitable 
radiolabel (Scheme 4.01). 
 
Scheme 4.01 Synthetic strategy to 11C labelled muscarinic receptor antagonist 
 
In the work published by Augelli-Szafran et al. they offer a suitable synthetic 
strategy to the target compounds 2 and 3.3  Thus, we planned to carry out the same 
synthetic procedures (Scheme 4.02) to afford 2 and 3.  Compound 3 exhibits high 
affinity for M1 muscarinic receptor with nano molar concentrations, as well as high 
specificity for the M1 subtype with respective affinities for M2-M5 subtypes at 102 
fold higher concentrations. 
 
N
O
O
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(i) PhLi, THF, -78 oC (ii) S8, ∆, PhCH3 (iii) conc. HCl, ∆ (iv) SOCl2, ∆ (v) 
cyclohexylmethanol, DCM, Et3N, 0 
oC to r.t. (vi) EtI, ∆ (vii) NaBH4, MeOH/H2O.   
Scheme 4.02 Synthetic strategy to 2 and 3 
 
Note:  While we propose the incorporation of 11C label, in practice we carry out the 
synthesis with 12C to demonstrate the required chemistry. 
 
Our first synthetic challenge was to synthesise 4,4-dimethyl-2-(pyridin-3-yl)-
4,5-dihydrooxazole prior to carrying out the synthesis described by Augelli-Szafran et 
al.  Our initial strategy (Scheme 4.03) while successful, did not give a satisfactory 
yield in the final cyclisation to afford the oxazoline.   
 
(i) SOCl3, ∆ (ii) 2-amino-2-methylpropan-1-ol, Et3N, 0 
oC to r.t (iii) SOCl2, r.t. 
Scheme 4.03 Synthesis of oxazoline precursor 
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At this point a literature search yielded a solution from the work carried out by 
Vorbrüggen and Krolikiewicz in 1993 which synthesised the desired oxazoline from 
nicotinic acid in one step (Scheme 4.04) by employing the Appel reaction in good 
yield.52 
 
(i) PPh3, 2-amino-2-methylpropan-1-ol, Et3N, CCl4, MeCN, 0 
oC to r.t, 24 hrs. 
Figure 4.04 Appel reaction of nicotinic acid to afford the desired oxazoline. 
 
 Our complete synthetic strategy is given in Figure 4.05 affording a mixture of 
2 and 3 from nicotinic acid. 
 
(i) PPh3, 2-amino-2-methylpropan-1-ol, Et3N, CCl4, MeCN, 0 
oC to r.t. (ii) PhLi, THF, -
78 oC (iii) S8, ∆, PhCH3 (iv) conc. HCl, ∆ (v) SOCl2, ∆ (vi) cyclohexylmethanol, DCM, 
Et3N, 0 
oC to r.t. (vii) EtI, ∆ (viii) NaBH4, MeOH/H2O, ∆. 
Figure 4.05 Complete synthetic strategy to 2 and 3. 
 
We are pleased to report the syntheses of 2 and 3 utilising a robust and reproducible 
synthetic protocol.  Having carried out the syntheses of 2 and 3 without considering 
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the time restrictions of the N-ethylation and sodium borohydride reductions we have 
achieved similar yields to that reported by Augelli-Szafran et al. 
 Following this we attempted the “hot steps” as could be performed in the 
synthesis of a PET contrast agent with 11C.  Again, we are pleased to report this was 
carried out in glassware with 18% and 5% yields for N-ethylation and reduction 
respectively.  While the reactions can be carried out in acceptable yields given the 
time constraints we have yet to demonstrate a purification protocol to yield 2 and 3. 
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5.0 CONCLUSION 
M1 MUSCARINIC RECEPTOR AGONIST 1 
Having carried out kinetic studies into the N-methylation and regio-selective 
reduction of pyridine and isoquinoline models we felt these models studies were 
transferable to the target compound 1.  Despite the difficulties with a novel synthetic 
route to 1 in the first instance, we are confident that we will be able to fully 
synthesise 1 by our second synthetic strategy and hope to complete this work to 
demonstrate accessibility to a range of C-functionalised morpholine moieties. 
 By demonstrating our “hot step” protocol, we hope to transfer our findings to 
new examples of M1 muscarinic receptor antagonists.  It is hoped this will add to our 
understanding of the M1 muscarinic receptor and ultimately allow the development of 
highly specific M1 muscarinic receptor agonists/antagonists.  By characterising these 
receptors using PET we would hope suitable targets can be identified for 
development to a viable treatment to slow the progression of AD. 
 
M1 MUSCARINIC RECEPTOR ANTAGONIST 2 AND 3 
Having demonstrated the synthesis of 2 and 3 in glassware in yields 
acceptable to the application of PET imaging we are looking to develop a robust 
purification protocol. As a result we have turned our attention to offering a HPLC 
(high performance liquid chromatography) protocol to yield 2 and 3.  Currently our 
work has showed good promise with the racemic mixture of 2 and 3 separable on 
reverse-phase HPLC (HPLC conditions: Hi Chrom C18, 4.6 x 150 mm, 
MeOH:H2O:0.01% TEA, 0.5 mL/min; 10 min).  Elution times vary between 3 – 6 min 
for compounds 2 and 3.  We are currently optimising the conditions to separate 2 
and 3 in a reproducible manner. 
In the future we look to not only offer a process of separation of 2 and 3, but 
also the separation of the two enantiomers of 3 by employing a Diacel ChiralPak OD 
column.  This would allow in vitro assays to be carried out on both the R and S forms 
of 3. 
  Aside from this work we are looking to carry out the borohydride reduction in 
flow with the HPLC purification.  This is carried out with polymer supported 
borohydride packed into a 100 mm HPLC column.  Currently we have achieved the 
required reduction; however, the current yield is < 1%.  To address this issue we 
plan to employ the use of a column oven to achieve greater yield.  Once this process 
 
52 
has been refined we will be able to offer the reduction and purification in < 10 min.  
This would constitute a significant step forward and a viable method for introducing 
11C radiolabels into similar compounds.  We plan to develop this process for both N-
methyl and N-ethyl series of our compounds. 
 While this work was carried out, the efficient N-methylation and borohydride 
reduction with the use of 11C methyliodide has been published by our partners in 
Caen.  While this was disappointing we are confident that by developing our protocol 
onto a flow system we can add value to the work already carried out by Gourand et 
al.53 
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6.0 EXPERIMENTAL 
Thin layer chromatography was carried out on aluminium-backed plates 
coated with 0.25 mm Merck Kiesel 60 F254 silica gel.  The plates were visualised by 
ultra violet irradiation at a wavelength of 254 nm.  Flash chromatography was carried 
out using Merck Kiesel gel 60 (70-230 mesh). 
 Infrared spectra were carried out using Perkin-Elmer Paragon 1000 FT-IR 
spectrophotometer in the range of 4000-600 cm-1.  Samples were dissolved in an 
appropriate solvent and applied to sodium plates as thin films.  In the case of liquid 
samples, they were applied neat as a thin film on sodium plates.  Only major 
absorbances have been quoted. 
 1H-NMR and 13C-NMR spectra were measured using either a Varian Gemini 
300 MHz spectrometer or Varian Lambda 400 MHz spectrometer.  The solvent used 
is stated using TMS (trimethylsilane) as the internal standard. 
The following references have been used in the description of NMR spectra: δ = 
chemical shift (in ppm), J = coupling constant (in Hz), s = singlet, br s = broad 
singlet, d = doublet, dd = double doublet, dt = double triplet, dq = doublet quartet, t = 
triplet, m = multiplet, Cq = quaternary carbon determined by DEPT. 
 Melting points were obtained using an Bϋchi B-545 melting point instrument 
and are uncorrected. 
 Unless otherwise stated all chemicals of reagent grade were obtained from 
Sigma-Aldrich. 
 
NMR studies into N-methylation of pyridine 
Pyridine-d5 (0.15 mL, 2 mmol) and iodomethane (0.1 mL, 1.6 mmol)  was added to 
MeOD (0.45 mL) in a NMR tube.  The 1H NMR spectra (300 MHz) were monitored 
every two minutes for an eight minute period in total (Figure 2.08).  Care was taken 
in the use of MeOD outside of fume hood. 
 
Preparation of 1-methylpyridinium iodide – 2 hours54 
 
Pyridine (4.5 mL, 4.7 g, 0.06 mol) in methanol (35 mL) was added to a round 
bottomed flask fitted with condenser, drying tube and pressure-equalising dropping 
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funnel.  The dropping funnel was charged with iodomethane (3.1 mL, 7.1 g, 0.05 
mol) and added dropwise (c.a 5 min).  The reaction mixture was stirred at room 
temperature for two hours.  Solvent was removed in vacuo, the yellow crystalline 
solid washed with diethyl ether and dried in vacuo to yield the title compound (9.34 g, 
62%); m.p. 113.1 oC (lit. 116-117 oC); IR νmax (DCM)/cm
-1 3037 (C-H alkene), 1631 
(C=C alkene), 1484 (C-H alkane), 1285 (C-N amine), 764 (C-H alkene); 1H NMR 
(400 MHz, CDCl3) δ 9.17 (2 H, d, J = 8.0, CHAAr), 8.42 (1 H, t, J = 8.0, CHCAr), 8.04 
(2 H, t, J = 8.0, CHBAr), 4.66 (3 H, s, CH3); 
13C NMR (75 MHz, CDCl3) δ 146.2 (CH 
Ar), 145.1 (CH Ar), 48 (CH3). 
 
1H NMR assignments 
 
General procedure for the preparation of 1-methylpyridinium iodide – 3 mins54 
 
Pyridine (4.5 mL, 4.7 g, 0.06 mol) in methanol (35 mL) was added to a round 
bottomed flask fitted with condenser, drying tube and heated to required temperature 
(Table 5.0).  Iodomethane (3.1 mL, 7.1 g, 0.05 mol) was added and the reaction 
stirred at a set temperature for three minutes.  Solvent was removed in vacuo, the 
yellow crystalline solid washed with diethyl ether and dried in vacuo to yield the title 
compound in its respective yield (Table 6.0). 
Time 
(min) 
Temperature 
(oC) 
Concentration 
of pyridine 
(mol) 
Concentration of 
MeI (mol) 
Yield of 2 (% from 
pyridine) 
120 25 0.06 0.05 62% 
3 30 0.06 0.05 nil 
3 35 0.06 0.05 nil 
3 40 0.06 0.05 4% 
3 45 0.06 0.05 7% 
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3 50 0.06 0.05 8% 
3 55 0.06 0.05 10% 
3 60 0.06 0.05 14% 
3 reflux 0.06 0.05 16% 
 
Table 6.0 Kinetic studies for N-methylation of pyridine 
 
Preparation of 2-methylisoquinolinium iodide54 
 
Isoquinoline (7.11 mL, 7.75 g, 0.06 mol) in methanol (35 mL) was added to a round 
bottomed flask fitted with condenser, drying tube and pressure equalising dropping 
funnel.  The dropping funnel was charged with iodomethane (3.1 mL, 7.1 g, 0.05 
mol) and added dropwise (c.a 10 min).  The reaction mixture was stirred at room 
temperature for two hours.  Solvent was removed in vacuo, the yellow crystalline 
solid washed with diethyl ether and dried in vacuo to yield the title compound (11.49 
g, 85%); m.p 159.9-161.1 oC (lit. 160-162 oC); IR νmax (DCM)/cm
-1 3062 (C-H 
alkene), 2961 (C-H alkane), 1649 (C-H phenyl), 1605 (C=C Ar), 1391 (C-H alkane), 
1178 (C-N amine), 811 (C-H phenyl), 756 (C-H phenyl); 1H NMR (300 MHz, CDCl3) δ 
10.71 (1H, s, CHGAr), 8.74 (1H, dd, J = 8.4, 1.2, CHBAr), 8.64 (1H, d, J = 8.4, 
CHAAr), 8.37 (1H, d, J = 6.6, CHFAr), 8.13 (1H, dd, J = 6.6, 1.2, CHEAr), 8.08 (1H, 
dd, J = 6.6, 1.2, CHDAr), 7.91 (1H, dd, J = 6.6, 1.5, CHCAr), 4.73 (3H, s, CH3); 
13C 
NMR (75 MHz, CDCl3) δ 150.9 (CH Ar), 137.3 (CH Ar), 136.3 (CH Ar), 131.0 (CH 
Ar), 130.2 (CH Ar), 127.5 (CH Ar), 127.0 (CH Ar), 125.0 (CH Ar), 120.0 (CH Ar), 48.6 
(CH3).  
 
 
1H NMR assignments 
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Preparation of 2-methyl-1,2,3,4-tetrahydroisoquinoline – 20 mins55 
 
2-Methyl isoquinolinium iodide (3 g, 0.021 mol) in methanol (20 mL) and water (10 
mL) was cooled to 0 oC.  Sodium borohydride (3 g, 0.072 mol) was added in portions 
(c.a 5 mins) then rapidly heated to reflux for 15 mins.  Once cooled the reaction 
mixture was washed with a saturated aqueous solution of ammonium chloride and 
extracted into diethyl ether.  Concentration in vacuo  and purification by distillation 
afforded the title compound as a colourless oil (1.60 g, 52%); b.p 88 oC (11 mbar); IR 
νmax (DCM)/cm
-1 3055 (C-H alkene), 2971 (C-H alkane), 1610 (C=C Ar), 1380 (C-H 
alkane), 1178 (C-N amine); 1H NMR (300 MHz, CDCl3) δ 7.53 (1H, d, J = 7.2, 
CHCAr), 7.45 (1H, dd, J = 7.2, 3.0, CHDAr), 7.20 (1H, dd, J = 7.2, 2.8, CHEAr), 7.15 
(1H, d, J = 7.2, CHFAr), 3.55 (2H, s, CH2G), 2.91 (2H, t, J = 8.0, CH2B), 2.64 (2H, t, J 
= 8.0, CH2A), 2.42 (3H, s, CH3); 
13C NMR (75 MHz, CDCl3) δ 137.2 (CH Ar), 136.0 
(CH Ar), 129.9 (CH Ar), 125.8 (CH Ar), 124.5 (CH Ar), 124.0 (CH Ar), 59.8 (CHx 
alkane), 55.2 (CHx alkane), 46.0 (CHx alkane), 30.0 (CHx alkane).  
 
1H NMR assignments 
 
Preparation of 2-methyl-1,2,3,4-tetrahydroisoquinoline – 8 mins 
 
2-Methyl isoquinolinium iodide (3 g, 0.021 mol) in methanol (20 mL) and water (10 
mL) was cooled to 0 oC.  Sodium borohydride (3 g, 0.072 mol) was added in portions 
(c.a 2 mins) then rapidly heated to reflux for 6 mins.  Once cooled the reaction 
mixture was washed with a saturated aqueous solution of ammonium chloride and 
extracted into diethyl ether.  Concentration in vacuo and purification by distillation to 
afford the title compound as a colourless oil (0.82 g, 27%). 
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Preparation of 2-chloro-1-(pyridin-3-yl)ethanone50 
 
Glacial acetic acid (15 mL) was cooled to 17 oC with stirring in a sealed test tube and 
HCl gas bubbled through the solution for two hours.  HCl gas was produced by 
adding conc. sulphuric acid dropwise to sodium chloride with stirring.  3-Acetyl 
pyridine (1 g, 0.9 mL, 0.0075 mol) was added dropwise to the acetic acid (c.a 20 
mins) and stirred for one hour.  N-Chlorosuccinimide (1.0 g, 0.0075 mol) was added 
to the reaction mixture at 20 oC with stirring overnight.  The reaction mixture was 
cooled to 15 oC and the precipitate filtered and then washed with acetic acid (at 17 
oC) then ethyl acetate (at 17 oC) and dried in vacuo to yield the title compound as a 
white crystalline solid (0.914 g, 71%); m.p 195.5-198 oC (dec) (lit. 200-201 oC (dec)); 
IR νmax (DCM)/cm
-1 3014 (C-H alkane), 1986 (C-H Ar), 1714 (C=O ketone), 1605 
(C=C Ar), 1342 (C-N amine); 1H NMR (300 MHz, DMSO-d6) δ 9.21 (1H, d, J = 3.0, 
CHD Ar), 8.91 (1H, dd, J = 6.0, 3.0, CHAAr), 8.51 (1H, dq, J = 6.0, 3.0, 0.6, CHCAr), 
7.79 (1H, dd, J = 6.0, 3.0, CHBAr), 5.28 (2H, s, CH2F); 
13C NMR (75 MHz, CDCl3) δ 
190.5 (CO), 149.7 (CH Ar), 145.0 (CH Ar), 140.1 (CH Ar), 131.6 (CqH Ar), 126.0 (CH 
Ar), 48.4 (CH2). 
 
1H NMR assignments 
 
Preparation of 2-chloro-1-(pyridin-3-yl)ethanol50 
 
A stirred solution of 2-chloro-1-(pyridin-3-yl)ethanone (0.5 g, 2.6 mmol) in methanol 
(10 mL) and water (5 mL) was cooled to 0 oC and sodium borohydride (129 mg, 3.34 
mmol) added in portions (c.a 30 mins).  The solution was allowed to warm to room 
temperature and stirred for a further two hours.  Solvent was removed in vacuo and 
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the residue dissolved in aqueous Na2CO3 and extracted with ethyl acetate.  The 
organic layer was dried over sodium sulphate, filtered and dried in vacuo to afford a 
viscous yellow oil.  The crude oil was purified by chromatography on silica eluting 
with hexane/ethyl acetate (5:1) to afford the title compound as viscous colourless oil 
(0.31 g, 75%); IR νmax (DCM)/cm
-1 3337 (O-H alcohol), 3014 (C-H alkane), 1986 (C-
H Ar), 1605 (C=C Ar), 1342 (C-N amine), 1205 (C-O alcohol); 1H NMR (300 MHz, 
DMSO-d6) δ 8.87(1H, dd, J = 3.0, 0.6 CHD Ar), 8.01 (1H, dd, J = 6.0, 3.0, CHAAr), 
7.87 (1H, dq, J = 9.0, 3.0, 0.6, CHCAr), 7.30 (1H, dd, J = 6.0, 3.0, CHBAr), 4.76 (1H, 
t, J = 7.0, CHF), 4.01 (2H, m, CHE), 3.55 (1H, m, OH); 
13C NMR (75 MHz, CDCl3) δ 
148.3 (CH Ar), 147.6 (CH Ar), 138.9 (CqH Ar), 134.5 (CH Ar), 124.0 (CH Ar), 79.2 
(CO), 49.4 (CH2).  
 
1H NMR assignments 
 
 
Preparation of 2-amino-1-(pyridin-3-yl)ethanol dihydrochloride50 
 
To a solution of 2-chloro-1-(pyridin-3-yl)ethanol (0.2 g, 1.3 mmol) in methanol (10 
mL) ammonium hydroxide (30%, 5 mL) was added and stirred at room temperature 
for 18 hours.  Methanol was removed in vacuo, one half of the water and ammonia 
was removed under vacuum distillation.  The remaining water and ammonia was 
removed as an azeotropic vacuum distillate with n-butanol.  HCl (37%) was added to 
the solution and concentrated in vacuo.  The precipitate was re-crystallised from 
absolute ethanol to yield the title compound as a white crystalline solid (0.09 g, 
41%); m.p 197.1-198.3 oC (lit. 199-201 oC);  IR νmax (DCM)/cm
-1 3337 (O-H alcohol), 
3014 (C-H alkane), 1986 (C-H Ar), 1605 (C=C Ar), 1367 (C-N amine), 1205 (C-O 
alcohol); 1H NMR (300 MHz, DMSO-d6) δ 8.86 (1H, dd, J = 3.0, 0.6 CHD Ar), 8.09 
(1H, dd, J = 6.0, 3, CHAAr), 7.77 (1H, m, CHCAr), 7.32 (1H, dd, J = 6.0, 3.0, CHBAr), 
N 
O
C l
H 
H F
H E 
H E 
H DHA
HB
H C 
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5.16 (2H, s, NH2), 4.76 (1H, t, J = 7.0, CHF), 3.55 (1H, m, OH), 3.30 (2H, m, CHE); 
13C NMR (75 MHz, CDCl3) δ 148.4 (CH Ar), 147.2 (CH Ar), 138.1 (CqH Ar), 134.8 
(CH Ar), 124.0 (CH Ar), 75.6 (CO), 44.0 (CH2).  
 
1H NMR assignments 
 
Preparation of nicotinoyl chloride56 
 
Thionyl chloride (24.6 g, 15 mL, 0.2 mol) was added to nicotinic acid (2 g, 16 mmol) 
and heated to reflux for 24 hours.  The reaction mixture was concentrated in vacuo, 
ether (50 ml) was added and concentrated in vacuo twice affording the acid chloride 
(2.25 g, quant.).  The white solid was carried through to the next step without 
characterisation. 
 
 
Preparation of N-(1-hydroxy-2-methylpropan-2-yl)nicotinamide56 
 
Nicotinoyl chloride (2.25 g, 16 mmol) was dissolved in DCM (20 ml) and added 
slowly to a cooled solution (0 oC) of 2-amino-2-methylpropan-1-ol in DCM (20 mL).  
Once addition was complete the reaction mixture was allowed to warm to room 
temperature and stirred for 24 hours, concentration in vacuo and purification by flash 
chromatography (silica, AcOEt) afforded the title compound as a white oil (1.3 g, 
42%); Rf 0.4 (silica, AcOEt); IR νmax (DCM)/cm
-1 3310 (N-H), 3270 (O-H), 3021 (C-H, 
alkene), 2856 (C-H, alkane), 1676 (C=O), 1264 (C-N), 1241 (C-O); 1H NMR (300 
MHz, DMSO-d6) δ 8.88 (1H, s, CHA), 8.46 (1H, d, J = 7.0,CHB), 8.31 (1H, d, J = 3.0, 
CHD), 7.56 (1H, dd, J = 3.0, 7.0, CHC), 6.03 (br, NH), 3.62 (1H, s, OH), 3.53 (2H, s, 
CHE), 1.30 (6H, s, CH3);  
13C NMR (75 MHz, DMSO-d6) δ 164.2 (CO), 157.1 (NCH), 
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149.0 (NCH), 134.0 (CH, Py), 129.5 (CH, Py), 126.3 (CH, Py), 74.7 (C(CH3)2), 61.0 
(COH), 29.9 (CH3). 
 
1H NMR assignments 
 
Preparation of 4,4-dimethyl-2-(pyridin-3-yl)-4,5-dihydrooxazole56 
 
Thionyl chloride (4.9 g, 3 mL, 0.58 mol) was added to N-(1-hydroxy-2-methylpropan-
2-yl)nicotinamide (1.3 g, 7 mmol) and stirred at room temperature for 16 hours.  The 
reaction mixture was concentrated in vacuo, dissolved in DCM (50 mL) and washed 
twice with NaOH solution (2 mol, 2 x 30 mL).  The organic layer was separated and 
dried overnight with MgSO4, filtered then concentrated in vacuo.  Purification by flash 
chromatography (silica, AcOEt) afforded the title compound as a brown viscous oil 
(0.32 g, 26%); Rf 0.40 (silica, AcOEt); IR νmax (DCM)/cm
-1 2968 (CH alkane), 1651 
(CN imine), 1591 (C=C Ar), 1386 (CN amine), 1243 (CO ether); 1H NMR (300 MHz, 
CDCl3) δ 9.02 (1H, s, CHA ), 8.57 (1H, dd, J = 4.9, 1.7 Hz, CHC), 8.14 – 8.05 (1H, m, 
CHB/D), 7.27 – 7.16 (1H, m, CHB/D), 4.01 (2H, s, CHE), 1.26 (6H, s, CH3); 
13C NMR 
(75 MHz, CDCl3) δ 159.2 (CN, imine), 150.9 (NCH), 148.5 (NCH), 134.6 (CH, Py), 
123.2 (CCN), 122.1 (CH, Py), 78.1 (CH2), 66.7 (C(CH3)), 27.2 (CH3). 
 
1H NMR assignments 
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Preparation of 4,4-dimethyl-2-(pyridin-3-yl)-4,5-dihydrooxazole57 
 
To a stirred solution of nicotinic acid (15 g, 0.12 mol), triphenylphosphine (90 g, 0.34 
mol), 2-amino-2,2-dimethylethanol (10.77 g, 11.6 mL, 0.12 mol) and triethylamine 
(98 g, 135 mL, 0.97 mol) in abs. acetonitrile (100 mL), a solution of 
carbontetrachloride (37.7 g, 23.8 mL, 0.24 mol) and abs. acetonitrile (36.5 mL) was 
added at 4 oC under nitrogen.  The solution was warmed to 9 oC for 4 hours and then 
allowed to warm to room temperature and stirred for a further 18 hours.  The 
precipitate was filtered and discarded; the dark brown filtrate was concentrated in 
vacuo.  The resulting dark brown residue was triturated with hexane (4 x 500 mL 
portions).  The remaining insoluble residue was dissolved in DCM (600 mL), hexane 
(1000 mL) was added to the solution and the resulting precipitate filtered and 
washed with hexane (500 mL).  The combined filtrates were concentrated in vacuo 
to afford the crude product.  Purification by vacuum distillation yielded the title 
compound as a brown viscous oil (13.96 g, 66%); b.p. 91 oC (3 mbar). 
 
Preparation of 4,4-dimethyl-2-(4-phenyl-1,4-dihydropyridin-3-yl)-4,5-
dihydrooxazole3 
 
Phenyllithium 1.9 M Cyclohexane/ether (7:3) (46 mL, 0.14 mol, 1.8 equiv) was added 
to a cooled solution (-78 oC) of 4,4-dimethyl-2-(pyridin-3-yl)-4,5-dihydrooxazole 
(13.96 g, 0.08 mol) in anhyd. THF (100 mL) under nitrogen and stirred for 3 hours.  
The reaction was quenched with water (100 mL) and left to warm to room 
temperature, ether (300 mL) was added to the reaction mixture.  The resulting 
precipitate was filtered, rinsed with chilled methanol (50 mL) and dried at 40 0C in a 
vacuum oven overnight to yield the title compound as a crude white solid (15.7 g, 
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78%); purification by flash chromatography was attempted with no pure product 
isolated, the crude solid was taken through to the next step. 
 
Preparation of 4,4-dimethyl-2-(4-phenylpyridin-3-yl)-4,5-dihydrooxazole3 
 
A suspension of 4,4-dimethyl-2-(4-phenyl-1,4-dihydropyridin-3-yl)-4,5-dihydrooxazole 
(15.7 g, 0.06 mol) and sulphur (16 g, 0.062 mol) in toluene (100 mL) was heated to 
reflux for 5 hours.  The reaction was allowed to cool to room temperature and 
filtered; the filtrate was concentrated in vacuo to yield the crude material.  Purification 
by vacuum distillation afforded the title compound as a viscous oil (12.4 g, 82%); b.p. 
153 oC (3 mbar); IR νmax (DCM)/cm
-1 2968 (C-H alkane), 1651 (C=N imine), 1636 
(C=C Ar), 1243 (C-O ether); 1H NMR (300 MHz, DMSO-d6) δ 7.98 (1H, s, CHA), 7.20 
(4H, m, CHD/E), 7.08 (1 H, m, CHF), 6.94 (1H, d, J = 8.0, CHC), 6.14 (1H, d, 8.0, 
CHB), 4.04 (2H, s, CHG ), 1.22 (6H, s, CH3); 
13C NMR (75 MHz, CDCl3) δ 163.1 (CN, 
imine), 152.3 (NCH), 150.7 (NCH), 148.1 (CCH Ar), 138.2 (CCH Py), 129.8 (CH Ar), 
128.1 (CH Ar), 127.2 (CH Ar), 125.1 (CH Py), 78.0 (CH2), 71.8 (CCH3), 28.0 (CH3). 
 
1H NMR assignments 
 
Preparation of 4-phenylnicotinic acid hydrochloride3 
 
4,4-Dimethyl-2-(4-phenylpyridin-3-yl)-4,5-dihydrooxazole (12.4 g, 0.05 mol) and 
concentrated HCl (25 mL) were heated to reflux for 24 hours.  The mixture was 
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allowed to cool to room temperature, filtered and the resulting solid washed with 
chilled 1 mol HCl.  The white solid was dried overnight at 40 oC under vacuum to 
yield the title compound (10.9 g, 93%); IR νmax (DCM)/cm
-1 3333 (O-H), 2963 (C-H 
alkane), 1672 (C=O), 1636 (C=C Ar), 1243 (C-O ether); 1H NMR (300 MHz, DMSO-
d6) δ 11.05 (1H, s, OH), 9.04 (1H, s, CHA), 8.87 (1H, d, J = 5.6 Hz, CHB), 7.77 (1H, d, 
J = 5.6 Hz, CHC), 7.61 – 7.30 (5H, m, CHD,E,F); 5.72 (broad signal, NH); 
13C NMR (75 
MHz, DMSO-d6) δ 164 (CO), 157 (CCH, Py) 146 (NCH), 144 (NCH), 138 (CCH, Ar), 
128 (CH, Ar), 127 (CH, Ar), 127 (CH, Ar), 125 (CCOOH), 123 (CH, Py). 
 
1H NMR assignments 
 
 
Preparation of 4-phenylnicotinoyl chloride3 
 
Thionyl chloride (50 mL) was added to 4-phenylnicotinic acid hydrochloride (10.9 g, 
46 mmol) and heated to reflux for 24 hours.  The mixture was allowed to cool to 
room temperature and concentrated in vacuo, ether (50 mL) was added to the 
resulting oil and concentrated in vacuo two times to yield a viscous colourless oil 
(10.01 g, quant.).  The oil was carried through to the following step without 
characterisation.   
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Preparation of cyclohexylmethyl 4-phenylnicotinate3 
 
4-Phenylnicotinoyl chloride (10.01 g, 0.046 mol) was diluted in DCM (25 mL) and 
added slowly to a cooled solution (0 oC) of cyclohexanemethanol (5.84 g, 6.26 mL, 
0.051 mol) and diisopropylethylamine (6.60 g, 8.9 mL, 0.051 mol) in DCM (50 mL).  
Once addition was complete, the reaction mixture was allowed to warm to room 
temperature and stirred for 24 hours.  The reaction mixture was quenched with 
aqueous saturated NaHCO3 solution (50 mL) and extracted twice with DCM (2 x 50 
mL).  The organic layer was dried overnight (MgSO4), filtered and concentrated in 
vacuo to afford the crude product.  Purification over silica (eluting with 30% 
EtOAc:hexane) yielded the title compound as a brown oil (8.01 g, 59%); Rf 0.8 
(silica, 30% EtOAc:hexane); IR νmax (DCM)/cm
-1 3001 (C-H, alkene), 2957 (C-H 
alkane), 1672 (C=O), 1636 (C=C Ar), 1255 (C-O ether); 1H NMR (300 MHz, CDCl3) δ 
9.02 (1H, s, CHA), 8.70 (1H, s br, CHB), 7.41 (4H, m, CHD,E), 7.31 (2H, m, CHC,F), 
3.87 (2H, d, J = 6.4, CHG), 1.72 (1H, m, CHH), 1.59 (4H, m, CHI), 1.37 (4H, m, CHJ), 
1.20 (2H, m, CHK); 
13C NMR (75 MHz, CDCl3) δ 166.3 (CO), 150.5 (NCH), 149.2 
(NCH), 138.7 (CCH, Py), 127.3 (CH, Ar), 127.8 (CH, Ar), 127.0 (CH, Ar), 124.5 
(CCO), 69.7 (CH2), 35.1 (CH), 28.3 (CH2), 25.2 (CH2), 24.0 (CH2). 
 
1H NMR assignments 
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Preparation of 3-((cyclohexylmethoxy)carbonyl)-1-ethyl-4-phenylpyridinium 
iodide3 
 
Ethyliodide (9.75 g, 5 mL, 63 mmol) was added to cyclohexylmethyl 4-
phenylnicotinate (0.5 g, 1.6 mmol) and heated to reflux for 24 hours.  The reaction 
mixture was then concentrated in vacuo to yield the title compound (0.76 g, quant.); 
IR νmax (DCM)/cm
-1 2887 (C-H, alkene), 2957 (C-H alkane), 1673 (C=O), 1640 (C=C 
Ar), 1337 (C-N), 1260 (C-O ether); 1H NMR (300 MHz, CDCl3) δ 9.88 (1H, d, J = 6.4, 
CHB), 9.32 (1H, s, CHA), 8.12 (1H, d, J = 6.4, CHC), 7.59 (3H, m, CHE,F), 7.46 (2H, 
dd, J = 4.0, 2.2, CHD), 5.10 (2H, m, CHL), 3.95 (2H, d, J = 8.4, CHG), 1.78 (3H, t, J = 
7.3, CHM), 1.57 (1H, m, CHH), 1.36 (4H, m, CHI), 1.08 (4H, m, CHJ), 0.67 (2H, m, 
CHK); 
13C NMR (75 MHz, CDCl3) δ 162.3 (CO), 157.2 (CCH, Py) 145.0 (CH, Py), 
143.8 (CCH, Py), 134.4 (CCH, Ar), 130.1 (CH, Ar), 129.1 (CH, Ar), 129.6 (CH, Ar), 
128.5 (CCO, Py), 127.1 (CH, Py), 71.0 (OCH2), 56.4 (NCH2), 35.6 (CH), 28.4 
(CHCH2), 24.6 (CH2), 24.4 (CH2), 15.3 (CH3). 
 
1H NMR assignments 
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Preparation of cyclohexylmethyl 1-ethyl-4-phenyl-1,2,3,6-tetrahydropyridine-3-
carboxylate (2) and cyclohexylmethyl 1-ethyl-4-phenyl-1,2,5,6-
tetrahydropyridine-3-carboxylate (3)3 
 
NaBH4 (0.56 g, 15 mmol) was added portion wise to a cooled a solution (0 
oC) of 3-
((cyclohexylmethoxy)carbonyl)-1-ethyl-4-phenylpyridinium iodide (0.75 g, 1.6 mmol) 
in MeOH (5 mL) and water (5 mL) NaBH4 (0.56 g, 15 mmol) with stirring.  The 
reaction mixture was allowed to warm to room temperature and stirred for 1.5 hours.  
The reaction was quenched with conc. HCl (4 mL) and neutralised with NH4OH 
solution (pH 8).  The mixture was extracted 3 times with EtOAc, concentration in 
vacuo afforded a mixture of 2 and 3 as a 1:1 mixture (0.483 g, 92%).  Purification by 
flash chromatography yielded 2 (0.034 g, 6%) and 3 (0.038 g, 7%).   
 
Compound 2: Rf 0.45 (silica, 25% EtOAc:Hexane); IR νmax (DCM)/cm
-1 2890 (C-H, 
alkene), 2950 (C-H alkane), 1675 (C=O), 1652 (C=C, alkene),1641 (C=C Ar), 1320 
(C-N), 1266 (C-O ether); 1H NMR (300 MHz, CDCl3) δ 7.43 (5H, m, CHD,E,F), 3.83 
(1H, s, CHA), 3.67 (2H, d, J = 11.4, CHG), 3.55 (1H, d, J = 7.9, CHB), 3.43 (2H, m, 
CHL), 3.25 (3H, m, CHM), 3.07 (1H, d, J = 7.9, CHC), 3.88 (2H, m, CHK), 1.46 (8H, m, 
CHI,J); 
13C NMR (75 MHz, CDCl3) δ 167.6 (C=O), 144.2 (CC, Py), 142.0 (CC, Ar), 
128.3 (CH, Ar), 126.0 (CH, Ar), 121.0 (CCO), 63.6 (O-CH2), 52.5 (CH, Py), 51.9 
(CH2, Et), 48.0 (CH, Py), 36.3 (CH, Hex), 28.2 (CH, Py), 24.6 (CH2, Hex), 17.1 (CH2, 
Hex), 14.2 (CH2, Hex), 13.1 (CH3); mass: m/z (%) = 327.23 (100). 
 
1H NMR assignments 
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Compound 3: Rf 0.3 (silica, 25% EtOAc:Hexane); IR νmax (DCM)/cm
-1 2866 (C-H, 
alkene), 2953 (C-H alkane), 1672 (C=O), 1655 (C=C, alkene),1645 (C=C Ar), 1313 
(C-N), 1256 (C-O ether); 1H NMR (300 MHz, CDCl3) δ 7.27 (5H, m, CHD,E,F), 6.09 
(1H, t, J = 3.0, CHC), 4.05 (2H, m, CHG), 2.92 (3H, m, CHA,N), 2.80 (2H, m, CHB), 
2.39 (2H, q, J = 12, CHL), 2.06 (1H, m, CHH), 1.58 (4H, m, CHI), 1.52 (4H, m, CHJ), 
1.37 (2H, m, CHK), 1.15 (3H, m, CHM);  
13C NMR (75 MHz, CDCl3) δ 167.2 (C=O), 
144.7 (CC, Py), 142.2 (CC, Ar), 128.0 (CH, Ar), 126.3 (CH, Ar), 115.1 (C=C, Py), 
63.8 (O-CH2), 52.6 (CH, Py), 51.5 (CH2, Et), 48.0 (CH, Py), 36.3 (CH, Hex), 28.1 
(CH, Py), 24.2 (CH2, Hex), 17.5 (CH2, Hex), 14.3 (CH2, Hex), 13.9 (CH3); mass: m/z 
(%) = 327.22 (100). 
 
 
1H NMR assignments 
 
All physical and spectroscopic data were consistent with those reported. 
 
6.1 MOLECULAR MODELLING 
Sybyl version X (Tripos - Sybyl X) was used for all construction of analogues 
and their resulting conformers, COMFA (comparative molecular field analysis) and 
PLS (partial least square) analyses.  Prior to minimisations, all analogues were 
generated from similar molecules of known X-ray crystallographic structures 
obtained from the Conquest (linux OS) database. 
Protein homology modelling was performed initially in clusta w (web based 
sequence alignment tool) and verified against multalin (web based sequence 
alignment tool) to determine a primary sequence with adequate similarity, with 
primary structures sourced from the protein data bank.  Determination of secondary 
and tertiary structures was obtained utilising atome (web based modelling tool) 
before importing into Sybyl X to carry out docking studies.   
  
GENERATION OF ANALOGUES
Two suitable structures were sourced from Conquest database as a suitable 
starting point to construct a range of analogues for the docking st
 
Figure 6.0 X-ray structures for modelling of analogues A (left) and B (right) 
 
A range of analogues were selected from the original publication by Augelli
Szafran et al (Table 6.01). 
Compound Motif
4 B 
5 B 
6 A 
7 A 
8 B 
9 B 
10 A 
11 A 
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udies (Figure 
 
respectively. 
 Isomer R 
R (CH2)5CH3 
S (CH2)5CH3 
- CH2C6H11 
- C6H11 
R C6H11 
S C6H11 
- (CH2)2Ph 
- CH2CH(CH3)2 
6.0). 
 
-
IC50 (nM) 
27.3 
27.3 
14.5 
18.1 
16.9 
16.9 
9.6 
120.5 
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12 B R CH2CH(CH3)2 128 
13 B S CH2CH(CH3)2 128 
14 A - (CH2)9CH3 106.1 
15 B R (CH2)2Ph-p-OCH3 159 
16 B S (CH2)2Ph-p-OCH3 159 
17 A - CH3 2308 
18 B R CH3 33117 
19 B S CH3 33117 
20 A - Ph 1819 
21 A - CH2CH3 888 
22 A - (CH2)2Ph-p-OCH3 1941 
 
Table 6.01 Analogues selected for modelling analysis  
 
ENERGY MINIMISATION 
All minimisations were carried out using a Fletcher-Powell method, 
considering both electrostatic and Van der Waals forces.  The end point of the 
process was determined by the gradient with a force field parameter of 0.05 kcalmol-
1, typically the end point was reached within 500 iterations.  The bond rotations 
considered and their respective degrees of freedom are defined in Figure 6.01 and 
Table 6.01. 
 
 
Figure 6.01 Analogues A and B (atom labelled). 
 Bond Degree of Freedom   Bond Degree of Freedom 
A 1-2 10o B 1-2 10o 
A 2-3 bond cleavage* B 2-3 10o 
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A 3-4 10o B 3-4 bond cleavage* 
A 4-5 10o B 4-5 10o 
A 1-6 10o B 5-6 10o 
A 6-7 60o B 6-7 60o 
A 3-8 30o B 3-8 30o 
A 8-9 30o B 8-9 30o 
A 5-10 60o B 5-10 60o 
A 10-11 1800 B 10-11 1800 
A 11-13 30o B 11-13 30o 
 
*A single cleavable bond is defined in the pyridinal ring to allow the software to ring 
flip to find the lowest energy state. 
Table 6.01 Defined degrees of freedom for conformational analysis. 
 
The conformational analysis afforded a range of structures for each analogue, 
the relative conformational energy was calculated for all conformers and the lowest 
energy conformation was selected to proceed into the docking experiment.  A full 
database of the data obtained from the conformational analysis can be found in 
Appendix 1. 
COMFA analysis was performed on all analogues by identification of 
pharmacophore (Figure 6.02) and superimposing the analogues on each other 
(Appendix 1).  A summary of the results are given in Table 6.02. 
 
Figure 6.02 Identified pharmacophore for COMFA analysis 
Compound Motif Isomer COMFA Score IC50 (nM) 
4 B R 81 27.3 
5 B S 82 27.3 
6 A - 80 14.5 
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7 A - 78 18.1 
8 B R 77 16.9 
9 B S 75 16.9 
10 A - 82 9.6 
11 A - 73 120.5 
12 B R 67 128 
13 B S 68 128 
14 A - 94 106.1 
15 B R 86 159 
16 B S 83 159 
17 A - 61 2308 
18 B R 62 33117 
19 B S 60 33117 
20 A - 71 1819 
21 A - 65 888 
22 A - 83 1941 
 
Table 6.02 Summary of results from COMFA analysis 
 
 
PROTEIN HOMOLOGY MODELLING 
Primary sequences of β2 adrenergic and M1 muscarinic receptors were 
obtained from protein data bank (PDB) and initial sequence homology performed by 
blast p (web based homology program) yielding a 95% agreement in the primary 
sequence.  The sequence alignment was performed by two independent programs 
(mustalin and clusta w) and gave good agreement with helical alignment and 
conservation of di-sulfide bridges. 
The aligned sequences from the analysis by clusta w was taken forward to 
construct a model of the M1 muscarinic receptor based on β2 adrenergic receptor.  
The aligned sequence (Appendix 2) was submitted to atome (web based program) to 
construct an initial model for M1 muscarinic receptor.  Upon detailed analysis of 
helical structures it was deemed a suitable model with no need to insert point 
mutations.  There was good conservation of all 7 helices and di-sulfide bridges 
 (Figure 6.03) (Appendix 2)
extracellular and the bottom intracellular, note the incorporation additional protein 
structure intracellular between helix 6 and 7, this was required to obtain the initial X
ray structure of β2 adrenergic receptor and thus was conserved in M1 muscarinic 
model.  This in no way impedes the binding of compounds as the active site is 
located extracellular helix 3.
Figure 
 
 
DOCKING STUDIES 
Key residues identified to generate the protomol (area in which molecule is to 
be docked) were defined: aspartic acid (105) and tyrosine (381).  Residues within 10 
angstrom radius of aspartic acid (105) were defined as important, yielding the 
protomol (Appendix 2). 
Each analogue (in its protonated form
active site and evaluated with respect to electrostatic and Van der
within the protomol.  A summary of the scores 
Compound Motif
4 B 
5 B 
6 A 
7 A 
73 
.  Figure 6.03 is orientated with the top of the model 
 
6.03 Model of M1 muscarinic receptor 
 – Figure 6.02) was docked into the 
 Waals interactions 
generated are given in Table 6.03
 Isomer Docking Score 
R 5.04 
S 4.34 
- 6.84 
- 4.46 
-
 
. 
IC50 (nM) 
27.3 
27.3 
14.5 
18.1 
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8 B R -* 16.9 
9 B S -* 16.9 
10 A - 5.12 9.6 
11 A - 4.53 120.5 
12 B R 4.23 128 
13 B S 3.61 128 
14 A - 5.45 106.1 
15 B R 3.81 159 
16 B S 5.64 159 
17 A - 2.48 2308 
18 B R 3.53 33117 
19 B S 2.65 33117 
20 A - 3.94 1819 
21 A - 3.93 888 
22 A - 4.88 1941 
*Compounds 8 and 9 were rejected from the docking study due to a steric clash with 
neighbouring residues. 
Table 6.03 Summary results of docking studies 
 
All data from docking studies can be found in Appendix 2.
 
vi 
ABBREVIATIONS  
Abs. Absolute  
Ac Acetyl 
 
AD Alzheimer’s disease  
Ar Aromatic  
BBB Blood brain barrier  
Boc Tert-butylcarbonate 
 
b.p. Boiling point  
CCR Chemokine receptor  
CNS Central nervous system  
conc. Concentrated  
Cq Quaternary carbon  
DCM Dichloromethane  
DMA Dimethylacetamide 
 
DMF Dimethylformamide 
 
Et Ethyl  
FDG 2-fluoro-2-deoxyglucose  
IC50 Half maximal inhibitory concentration  
Ki Dissociation constant  
LAH Lithium aluminium hydride  
mAChRs Muscarinic acetylcholine receptor  
Me Methyl  
m.p. Melting point  
NBS N-bromosuccinimide 
 
NCS N-chlorosuccinimide 
 
 
vii 
NMR Nuclear magnetic resonance  
PET Positron emission tomography  
Py Pyridine 
 
Quat. Quaternary  
RSA Retro-synthetic analysis  
SAR Structure-activity relationship  
TEA Triethyl amine 
 
Tf Trifluoromethane sulfonate 
S
O
O
O-
F
F
F
 
THF Tetrahydrofuran 
 
TLC Thin layer chromatography  
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APPENDIX 1 
• Database of comformers constructed with calculated physical data. 
 
APPENDIX 2 
• Protein homology modelling – sequence alignment, model files, results of 
docking study. 
 
